

STIC-ILL

105

104/26

From:
Sent:
T :
Subject:

Yaen, Christopher
Thursday, April 25, 2002 5:46 PM
STIC-ILL
09815306

Rm 270. J6

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mitra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

392 925

11696695

Christopher Yaen
Patent Examiner
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

Scientific and Technical
Information Center

APR 29 RECD

PAT. & T.M. OFFICE

672 7586

Scientific and Technical
Information Center

RECD

PAT. & T.M. OFFICE

STIC-ILL

NOV 4/26

From: Yaen, Christopher
Sent: Thursday, April 25, 2002 5:46 PM
T: STIC-ILL
Subject: 09815306

392901

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

11708720

Christopher Yaen
Patent Examiner
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

6721091

Scientific and Technical
Information Center

APR 26 RECD

PAT. & T.M. OFFICE

STIC-ILL

NPL

From: Yaen, Christopher
Sent: Thursday, April 25, 2002 5:46 PM
To: STIC-ILL
Subject: 09815306

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

Christopher Yaen
Patent Examiner
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

STIC-ILL

NPL

From: Yaen, Christopher
Sent: Thursday, April 25, 2002 5:46 PM
To: STIC-ILL
Subject: 09815306

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

Christopher Yaen
Patent Examiner
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002

=> file medline, cancerlit, caplus, embase, biosis, uspatfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 10:34:58 ON 25 APR 2002

FILE 'CANCERLIT' ENTERED AT 10:34:58 ON 25 APR 2002

FILE 'CAPLUS' ENTERED AT 10:34:58 ON 25 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:34:58 ON 25 APR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:34:58 ON 25 APR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 10:34:58 ON 25 APR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fusion protein? or chimera?
4 FILES SEARCHED...
L1 246870 FUSION PROTEIN? OR CHIMERA?

=> s il2 or interleukin 2 and il1
L2 17094 IL2 OR INTERLEUKIN 2 AND IL1

=> s il1 and interleukin 12 or il1 il2
L3 27059 IL1 AND INTERLEUKIN 12 OR IL 12

=> s il1 and interferon gamma or gamma interferon or ifn
L4 208008 IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN

=> s prolactin agonist
L5 10 PROLACTIN AGONIST

=> s prolactin antagonist
L6 80 PROLACTIN ANTAGONIST

=> s 16 not py=>2000
L7 55 L6 NOT PY=>2000

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)

=> d 18 1-35

L8 ANSWER 1 OF 35 MEDLINE DUPLICATE 1
AN 2000055692
DN 20055692 PubMed ID: 10589775
TI A human prolactin antagonist, hPRL-G129R, inhibits
CM breast cancer cell proliferation through induction of apoptosis.
ER:atum in: Clin Cancer Res 2000 May;6(5):2120
AU Chen W Y; Ramamoorthy P; Chen N; Sticca R; Wagner T E
CS Oncology Research Institute, Cancer Center, Greenville Hospital System,
South Carolina 29605, USA. wchen@ghs.org
SO CLINICAL CANCER RESEARCH. (1999 Nov) 5 (11) 3583-93.
Journal code: C2H; 9502500. ISSN: 1078-0432.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200001
ED Entered STN: 20000114
Last Updated on STN: 20000928
Entered Medline: 20000106

L8 ANSWER 2 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:193009 BIOSIS
DN PREV199900193009
TI Inhibitory effects of a prolactin antagonist in human
AU breast cancer cell proliferation and its synergistic action in conjunction
with tamoxifen.
AU Chen, W. Y. (1); Long, Y.; Ramamoorthy, P.; Wei, Y.; Sticca, R. P.;
Wagner, T. E.
CS (1) Oncol. Res. Div., Cancer Treatment Cent., Greenville Hosp. System,
Clemson, SC 29634 USA
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (March, 1999) Vol. 40, pp. 733.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer
Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American
Association for Cancer Research
ISSN: 0197-016X.

DT Conference
LA English

L8 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1999:647558 CAPLUS
DN 132:149813
TI Prolactin involvement in breast cancer
AU Vonderhaar, B. K.
CS Molecular and Cellular Endocrinology Section, Laboratory of Tumor
Immunology and Biology, National Cancer Institute, National Institutes of
Health, Bethesda, MD, 20892-1402, USA
SO Endocrine-Related Cancer (1999), 6 (3), 389-404
CODEN: ERCAE9; ISSN: 1351-0088

PB Society for Endocrinology
DT Journal; General Review
LA English
RE.CMT 158 THERE ARE 158 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1998:356025 CAPLUS
DN 129:118021
TI Prolactin is an antagonist of TGF-beta activity and promotes
AU proliferation of murine B cell hybridomas
AU Richards, Susan M.; Garman, Richard D.; Keyes, Lynne; Kavanagh, Brian;
MCPheron, John M.
CS Immunol. Lab., Dep. Cell Protein Therapeutics R & D, Genzyme Corp.,
Framingham, MA, 01701-9322, USA
SO Cell. Immunol. (1998), 184 (2), 85-91
CODEN: CLIMB8; ISSN: 0008-8749

PB Academic Press
DT Journal
LA English

L8 ANSWER 5 OF 35 USPATFULL
AN 97:3190 USPATFULL
TI Compositions and methods for treating exocrine gland atrophy
AU Kasanin, Renee, Athens, GA, United States
AU Mitcheff, Austin K., LaCrescenta, CA, United States

PA Warren, Dwight W., Granada Hills, CA, United States
University of Georgia Research Foundation, Athens, GA, United States
(U.S. corporation)

PI University of Southern California, Los Angeles, CA, United States (U.S. corporation)
US 5639743 19970617
US 1994-268971 19940630 (8)

AI Continuation of Ser. No. US 1992-975869, filed on 13 Nov 1992, now abandoned

DT Utility

FS Granted

LN.CNT 711

INCL INCLM: 514/171.000
INCLM: 514/177.000; 514/250.000; 514/254.000; 514/410.000
NCLM: 514/021.000
NCLM: 514/002.000; 514/171.000; 514/177.000; 514/250.000; 514/410.000

IC ICM: A61K031-56
ICS: A61K031-495; A61K031-50; A61K031-40
EXF 514/250; 514/254; 514/177; 514/171; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 35 MEDLINE
AN 1998068083 PubMed ID: 9404272
DN 98068083
TI Termination of diestrus and induction of oestrus in dioestrous nonpregnant bitches by the prolactin antagonist cabergoline.

CS Jeukene P; Versteegen J
AU Dept of Small Animal Reproduction, University of Liege, College of Veterinary Medicine Belgium
SO JOURNAL OF REPRODUCTION AND FERTILITY SUPPLEMENT, (1997) 51 59-66.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199801
ED Entered STN: 19980129
Last Updated on STN: 19980129
Entered Medline: 19980109

L8 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1996:423995 CAPLUS
DN 125:105329
TI Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay
AU Goffin, Vincent; Kinet, Sandrine; Ferrag, Fatima; Binart, Nadine; Martial, Joseph A.; Kelly, Paul A.
CS Endocrinol. Mol., INSERM, Paris, 75730, Fr.
SO J. Biol. Chem. (1996), 271(28), 16573-16579
CODEN: JBCHA3; ISSN: 0021-9256

DT Journal
LA English

L8 ANSWER 8 OF 35 MEDLINE
AN 95259840
DN 95259840 PubMed ID: 7741273
TI Disturbance of follicular development and endocrine reactions induced by the antiovarian effective progesterone antagonist Onapristone.

AU Schubert C; Nishino Y; Michna H
CS Forschungslaboratorien der Schering AG Berlin, Germany.
SO ANATOMISCHER ANZEIGER, (1995 Mar) 177 (2) 139-46.
Journal code: APE; 0370541. ISSN: 0003-2786.

CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199506
ED Entered STN: 19950615
Last Updated on STN: 19990129
Entered Medline: 19950602

L8 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1993:183694 CAPLUS
DN 118:183694
TI Mechanism-based design of prolactin receptor antagonists
AU Fuh, Germaine; Colosi, Peter; Wood, William I.; Wells, James A.
CS Dep. Protein Eng., Genentech, Inc., South San Francisco, CA, 94080-4990, USA
SO J. Biol. Chem. (1993), 268(8), 5376-81
CODEN: JBCHA3; ISSN: 0021-9256

DT Journal
LA English

L8 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1992:233518 CAPLUS
DN 116:233518
TI Effect of bromocriptine, a prolactin antagonist, on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and interleukin-2
AU Kumar, G. Sivan; Das, U. N.; Das, N. P.; Tan, B. K. H.
CS Dep. Med., Nizam's Inst. Med. Sci., Hyderabad, 500 482, India
SO Med. Sci. Res. (1992), 20(4), 141-2
CODEN: MSCREJ; ISSN: 0269-8951

DT Journal
LA English

L8 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS
AN 1992:504649 CAPLUS
DN 117:104649
TI Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the fat anterior pituitary
AU Pisarek, H.; Stepien, H.; Pawlikowski, M.
CS Inst. Endocrinol., Med. Acad., Lodz, 91-425, Pol.
SO Endocr. Regul. (1992), 26(1), 17-22
CODEN: EREGJ3

DT Journal
LA English

L8 ANSWER 12 OF 35 MEDLINE
AN 92170160
DN 92170160 PubMed ID: 1792797
TI Danazol in treatment of cystic mastopathy.
AU Danazol in der Behandlung der zystischen Mastopathie.
AU Radivojvic K
CS II. Universitäts-Frauenklinik, Wien.
CS WIENER KLINISCHE WOCHENSCHRIFT, (1991) 103 (23) 710-3.
SO Journal code: XOP; 21620870R. ISSN: 0043-5325.
Austria

CY (CONTROLLED CLINICAL TRIAL)
DT (RANDOMIZED CONTROLLED TRIAL)
Journal; Article; (JOURNAL ARTICLE)
German
FS Priority Journals
EM 199204

ED Entered STN: 19920417
 Last Updated on STN: 19970203
 Entered Medline: 19920402

L8 ANSWER 13 OF 35 MEDLINE
 AN 92005963
 DN 92005963 Pubmed ID: 1914033
 TI Treatment of breast proliferation disease with modified xiao yao san and
 AU Zhang G L
 SO Dept. of Surgery TCM, First Affiliated Hospital, Shanxi Medical College,
 Talyuan.
 CS CHUNG HSI I CHIEH HO TSA CHIH CHINESE JOURNAL OF MODERN DEVELOPMENTS IN
 TRADITIONAL MEDICINE, (1991 Jul) 11 (7) 400-2, 388.
 Journal code: CZU, 8207427. ISSN: 0254-9034.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA Chinese
 FS Priority Journals
 EM 199111
 ED Entered STN: 19920124
 Last Updated on STN: 19920124
 Entered Medline: 19911105

L8 ANSWER 14 OF 35 CANCERLIT
 AN 92005963 CANCERLIT
 DN 92005963
 TI Treatment of breast proliferation disease with modified xiao yao san and
 AU Zhang G L
 CS Dept. of Surgery TCM, First Affiliated Hospital, Shanxi Medical College,
 Talyuan.
 SO CHUNG HSI I CHIEH HO TSA CHIH CHINESE JOURNAL OF MODERN DEVELOPMENTS IN
 TRADITIONAL MEDICINE, (1991). Vol. 11, No. 7 400-2, pp. 388.
 Journal code: CZU. ISSN: 0254-9034.
 DT Journal: Article; (JOURNAL ARTICLE)
 FS MEDL: 1
 LA Chinese
 OS MEDLINE 92005963
 EM 199112

L8 ANSWER 15 OF 35 MEDLINE
 AN 92069294 MEDLINE
 DN 92069294 Pubmed ID: 1958840
 TI Physiological significance of hormones and related substances in milk with
 AU special reference to prolactin: an overview.
 CS Nagasawa H
 SO Experimental Animal Research Laboratory, Meiji University, Kanagawa,
 Japan.
 CS ENDOCRINE REGULATIONS, (1991 Jun) 25 (1-2) 90-7. Ref: 45
 Journal code: A73; 9112018. ISSN: 1210-0668.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA Czechoslovakia
 FS General Review; (REVIEW)
 EM (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199201
 ED Entered STN: 19920124
 Last Updated on STN: 19920124
 Entered Medline: 19920107

L8 ANSWER 16 OF 35 MEDLINE
 AN 90065446 MEDLINE
 DUPLICATE 7

DN 90065446 Pubmed ID: 2585998
 TI [Bromocriptine: a new therapy concept in the treatment of chronic
 recurrent uveitis?].
 AU Zierhut M; Pleyer U; Waectjen R; Thiel H J; Weidle E G
 CS Abteilung I, Universitäts-Augenklinik Tübingen.
 SO KLINISCHE MONATSBLÄTTER FÜR AUGENHEILKUNDE, (1989 Oct) 195 (4) 221-5.
 Journal code: KWA; 0014133. ISSN: 0023-2165.
 DT Journal: Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 198912
 ED Entered STN: 19900328
 Last Updated on STN: 19900328
 Entered Medline: 19891227

L8 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1987:423564 CAPLUS
 DN 107:23564
 TI Preparation of (+)-isochanoclavine-1
 IN Somei, Masanori
 PA Kissei Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokyo Koho, 5 pp.
 DT Patent
 LA Japanese
 FAN CMT 1

PI PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 62063569 A2 19870320 JP 1985-203890 19850913
 JP 02031347 B4 19900802

L8 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1986:219446 CAPLUS
 DN 104:219446
 TI Mechanisms of action inhibitors of prolactin secretion in GH3 pituitary
 AU Wolfe, Susan E.; Brostrom, Margaret A.
 CS Dep. Pharmacol., Univ. Med. Dent. New Jersey, Piscataway, NJ, 08854, USA
 SO Mol. Pharmacol. (1986), 29(4), 420-6
 CODEN: MOPMA3; ISSN: 0026-895X
 DT Journal
 LA English

L8 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1986:219445 CAPLUS
 DN 104:219445
 TI Mechanisms of action of inhibitors of prolactin secretion in GH3 pituitary
 AU Wolfe, Susan E.; Brostrom, Margaret A.; Brostrom, Margaret A.
 CS Dep. Pharmacol., Univ. Med. Dent. New Jersey, Piscataway, NJ, 08854, USA
 SO Mol. Pharmacol. (1986), 29(4), 411-15
 CODEN: MOPMA3; ISSN: 0026-895X
 DT Journal
 LA English

L8 ANSWER 20 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 86013861 EMBASE
 DN 1986013861
 TI Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT
 AU mouse mammary carcinoma.
 Zaccaro T.

CS Experimental Oncology, Farmitalia Carlo Erba Research Institute, 20014
 SO Nerviano, Milano, Italy
 Cancer Letters, (1985) 28/2 (237-241).
 CODEN: CALEDD

CY Ireland
 DT Journal

FS 037 Drug Literature Index
 003 Endocrinology
 010 Obstetrics and Gynecology
 016 Cancer
 009 Surgery
 030 Pharmacology
 LA English

L8 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:72129 CAPLUS
 DN 102:72129

TI Pharmacology of prolactin antagonists
 AU Jean-Joseph, Patricia; Bouchard, Philippe; Schaison, Gerard
 CS Serv. Endocrinol., Hop. Bicetre, Le Kremlin-Bicetre, 94270, Fr.
 SO Vie Med. (1984), 65(23), 911-12, 914, 917-18, 920
 CODEN: VIMEAL; ISSN: 0042-5591

DT Journal: General Review
 LA French

L8 ANSWER 22 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1985:48886 BIOSIS
 DN BR28:48886

TI ACCIDENTAL BROMOCRIPTINE INGESTION IN CHILDHOOD.
 AU VERMUND S H; GOLDSTEIN R G; ROMANO A A; ATWOOD S J
 CS DIV. EPIDEMIOLOG., 600 W. 168TH ST., NEW YORK, N.Y. 10032.
 SO J. Pediatr. (St. Louis), (1984) 105 (5), 838-840.
 CODEN: JOPDAB; ISSN: 0022-3476.
 FS BR: OLD
 LA English

L8 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1982:437077 CAPLUS
 DN 97:37077

TI A possible role of prolactin in adjuvant arthritis
 AU Bercei, I.; Nagy, E.
 CS Dep. Immunol., Univ. Manitoba, Winnipeg, MB, R3E 0W3, Can.
 SO Arthritis Rheum. (1982), 25(5), 591-4
 CODEN: ARHEAW; ISSN: 0004-3591

DT Journal
 LA English

L8 ANSWER 24 OF 35 MEDLINE
 AN 83006317 MEDLINE
 DN 83006317 PubMed ID: 6889585

TI The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
 AU Jeromin L
 SO INTERNATIONAL UROLOGY AND NEPHROLOGY, (1982) 14 (1) 51-6.
 Journal code: GUQ; 0262521. ISSN: 0301-1623.
 CY Hungary
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198212
 ED Entered STN: 19900317
 Last Updated on STN: 19900317
 Entered Medline: 19821202

L8 ANSWER 25 OF 35 CANCERLIT
 AN 81618709 CANCERLIT
 DN 81618709

TI ROLE OF PROLACTIN IN THE DEVELOPMENT OF MAMMARY GLAND TUMORS INDUCED BY DIETHYLENZANTHRACENE.
 AU Devov I I; Demina N A
 CS Lab. Experimental Biology of Tumors, Oncologic Scientific Center, Acad. Medical Sciences USSR, Moscow, USSR.
 SO Bull Exp Biol Med, (1981). Vol. 90, No. 9, pp. 1278-1280.
 ISSN: 0007-4888

DT Journal: Article; (JOURNAL ARTICLE)
 FS ICDB
 LA English
 EM 198107

L8 ANSWER 26 OF 35 MEDLINE
 AN 82089205 MEDLINE
 DN 82089205 PubMed ID: 7316110

TI Prolactin and contact sensitivity.
 AU Nagy E; Bercei I
 SO ALLERGY, (1981 Aug) 36 (6) 429-31.
 Journal code: 39C; 7804028. ISSN: 0105-4538.
 CY Denmark
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198202

ED Entered STN: 19900316
 Last Updated on STN: 19900316
 Entered Medline: 19820212

L8 ANSWER 27 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1982:171345 BIOSIS
 DN BA73:31329

TI THE IMPORTANCE OF PROLACTIN IN THE GESTATION OF THE ROE DEER CAPREOLUS-CAPREOLUS-CAPREOLUS.
 AU VON FISCHER B
 CS UNIV.-FRAUENKLIN. BERN, SCHANZENECKSTR. 1, CH-3012 BERN, SWITZ.
 SO Z. SAEGETIERKD, (1981) 46 (4), 259-264.
 CODEN: ZSAEA7; ISSN: 0044-3468.
 FS BA: OLD
 LA German

L8 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1980:52243 CAPLUS
 DN 92:52243

TI How can maternal lactation be inhibited?
 AU Baudet, J. H.; Pichereau, D.; Peter, J.; Brouquet, J.
 CS Hop. Univ. Dupuytren, Limoges, 87000, Fr.
 SO Gaz. Med. Fr. (1979), 86(33), 3795-6, 3798
 CODEN: GAMF7; ISSN: 0016-5557

DT Journal: General Review
 LA French

L8 ANSWER 29 OF 35 CANCERLIT
 AN 80654353 CANCERLIT
 DN 80654353

TI HYPERPROLACTINEMIA INDUCED BY ANTIEMETICS: COMPARISON OF FOUR DRUGS).
 AU Segrestaa U M; Guertis J; Julien D; Tiar M
 CS Unite de Recherche sur la Pathologie Iatrogene, Hopital Lariboisiere, 2, rue Ambroise Pare, 75010 Paris, France.
 SO Therapie, (1979). Vol. 34, No. 4, pp. 437-443.
 ISSN: 0040-5957.

DT Journal; Article; (JOURNAL ARTICLE)
 FS ICDB
 LA French
 EM 198006

L8 ANSWER 30 OF 35 MEDLINE
 AN 80116495 MEDLINE
 DN 80116495 Pubmed ID: 528777
 TI Influence of bromocriptine on plasma levels of prolactin and steroid hormones in the 20th week of pregnancy.
 AU Lehmann W D; Musch K; Wolf A S
 SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. (1979 Jul-Sep) 2 (3) 251-5.
 CY Journal code: IAM: 7806594. ISSN: 0391-4997.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198004
 ED Entered STN: 19900315
 Last Updated on STN: 19900315
 Entered Medline: 19800417

L8 ANSWER 31 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 79018228 EMBASE
 DN 1979018228
 TI [Prolactin and ovarian function].
 AU PROLATTINA E FUNZIONE OVARICA.
 AU Rendina M.; Donadio C.; Martore G.B.
 CS I Div. Ostet. Ginecol., Osp. San Camillo de Lellis, Roma, Italy
 SO Patologia e Clinica Ostetrica e Ginecologica, (1978) 6/4 (196-207).
 CY Italy
 DT Journal
 FS 037 Drug Literature Index
 010 Obstetrics and Gynecology
 003 Endocrinology
 030 Pharmacology
 LA Italian
 SL English

L8 ANSWER 32 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 78356542 EMBASE
 DN 1978356542
 TI Hormonal control of breast cancer growth in women and rats.
 AU Pearson O.H.; Manni A.
 CS Dept. Med., Case West. Reserve Univ. Sch. Med., Cleveland, Ohio, United States
 SO Current Topics in Experimental Endocrinology, (1978) VOL.3/- (75-92).
 CY CODEN: CTEEAJ
 DT United States
 FS 037 Drug Literature Index
 003 Endocrinology
 010 Obstetrics and Gynecology
 016 Cancer
 LA English

L8 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2002 ACS
 AN 1978:15598 CAPLUS
 DN 88:15598
 TI The treatment of various forms of ovarian insufficiency with prolactin-inhibiting substances
 AU Schulz, K. D.
 CS Univ.-Frauenklin. Koeln, Cologne, Ger.

SO Therapiewoche (1977), 27(1), 96-8, 101
 CODEN: THEWA6
 DT Journal; General Review
 LA German

L8 ANSWER 34 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 76182512 EMBASE
 DN 1976182512
 TI Galactorrhea: past and present concepts.
 AU Cooperstein M.S.
 CS Dept. Obstet. Gynecol., John F. Kennedy Mem. Hosp., Stratford, N.J.
 SO United States
 SO Journal of the American Osteopathic Association, (1975) 75/3 (334-339).
 CY CODEN: JAQAAZ
 DT Journal
 FS 037 Drug Literature Index
 010 Obstetrics and Gynecology
 003 Endocrinology
 009 Surgery
 006 Internal Medicine
 LA English

L8 ANSWER 35 OF 35 MEDLINE
 AN 60035327 MEDLINE
 DN 60035327
 TI Inactivation of prolactin by human blood serum and plasmin (fibrinolysin).
 AU HOPKINS T F; MEITES J; RAYNER A
 SO Proc Soc Exp Biol Med, (1961 Jan) 106 140-1.
 DT Journal
 LA English
 FS OLDMEDLINE
 EM 196112
 ED Entered STN: 19990716
 Last Updated on STN: 19990716

=> his
 HIS IS NOT A RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> d his
 (FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)
 FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFULL' ENTERED AT
 10:34:58 ON 25 APR 2002
 L1 246870 S FUSION PROTEIN? OR CHIMER?
 L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1
 L3 27059 S IL1 AND INTERLEUKIN 12 OR IL12
 L4 208008 S IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN
 L5 10 S PROLACTIN AGONIST
 L6 80 S PROLACTIN ANTAGONIST
 L7 55 S L6 NOT PY=>2000
 L8 35 DUP REM L7 (20 DUPLICATES REMOVED)

=> s L6 and L1
 L9 4 L6 AND L1

=> d L9 L1-4 ibib
 L9 ANSWER 1 OF 4 MEDLINE
 ACCESSION NUMBER: 2001095543 MEDLINE

PRIORITY APPL. INFO.:
 US 2000-191457P P 20000323
 INVENTOR(S):
 WALKER, ANNE M., RIVERSIDE, CA, United States
 { }
 PATENT INFORMATION:
 APPLICATION INFO.:
 NO 1997-US1435
 US 2001036662 A1 20011101
 US 1998-65330 A1 19980423 (9)
 WO 1997-US1435 19970130
 None PCT 102(e) date
 DOCUMENT TYPE:
 FILE SEGMENT:
 LEGAL REPRESENTATIVE:
 KNOBE MATTEUS OLSON & BEAR LLP, 620 NEWPORT CENTER
 DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
 NUMBER OF CLAIMS:
 EXEMPLARY CLAIM:
 NUMBER OF DRAWINGS:
 LINE COUNT:
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFULL' ENTERED AT 10:34:58 ON 25 APR 2002

L1 246870 S FUSION PROTEIN? OR CHIMER?
L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1
L3 27059 S IL1 AND INTERLEUKIN 12 OR IL12
L4 208008 S IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN
L5 10 S PROLACTIN AGONIST
L6 80 S PROLACTIN ANTAGONIST
L7 55 S L6 NOT PY=>2000
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)
L9 4 S L6 AND L1
L10 1358 S IMMUNOMODULATOR? AND L1
L11 1124 DUP REM L10 (234 DUPLICATES REMOVED)
L12 509 S L11 NOT PY=>2000
L13 100 S L12 AND INTERLEUKIN 2
L14 8 S L12 AND INTERFERON 12
L15 70916 S L12 AND INTERFERON GAMMA OR GAMMA INTERFERON
L16 76 S L12 AND GAMMA INTERFERON
L17 71 S L12 AND INTERFERON GAMMA

=> d 117 1-71

L17 ANSWER 1 OF 71 MEDLINE
AN 97405413 MEDLINE
DN 97405413 PubMed ID: 9262056
TI Molecular cloning and expression of a fungal immunomodulatory protein, Flp-five, from *Flammulina velutipes*.
AU Ko J L, Lin S J, Hsu C I, Rao C L, Lin J Y
CS Institute of Biochemistry, College of Medicine, National Taiwan University, Taipei, ROC.
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, (1997 Jul) 96 (7) 517-24.
CY TAINAN: Taiwan, Province of China
DT Journal: Article: (JOURNML ARTICLE)
LA English
FS Priority Journals
EM 199709
ED Entered STN: 19970926
Last Updated on STN: 19970926
Entered Medline: 19970916

L17 ANSWER 2 OF 71 MEDLINE
AN 92330820 MEDLINE
DN 92330820 PubMed ID: 1628125
TI The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice.
AU Biedler A, Weiss L, Slavin S
CS Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
SO BONE MARROW TRANSPLANTATION, (1992 Jun) 9 (6) 421-6.
CY ENGLAND: United Kingdom
DT Journal: Article: (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199208
ED Entered STN: 19920904
Last Updated on STN: 19920904
Entered Medline: 19920820

L17 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2002 ACS

AN 1999:592512 CAPLUS
DN 132:92016
TI Effect of different adjuvants and immunomodulators on the humoral immune response of rabbits and mice against HIV-1-derived multi-epitope polypeptides

AU Herrera, Antonieta M.; Vazquez, Dania; Navea, Leonor; Lobaina, Leonor; Quintana, Diogenes; Napoles, Annara; Garcia, Yanela; Duarte, Carlos A.
CS Vaccine Division, AIDS Department, Center for Genetic Engineering and Biotechnology, Havana, 10600, Cuba
SO Biotechnology Applied (1999), 16(2), 103-108
CODEN: BTAPEP, ISSN: 0864-4551
PB Sociedad Iberoamericana de Biociencia Aplicada a la Salud
DT Journal
LA English
RE.CNT 28
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2002 ACS

AN 1999:309088 CAPLUS
DN 131:143197
TI Construction of chimeric immunogens: Bioactive fragment of human IL-1-beta, or polyuftsln (PF) capable of eliciting immune responses to HIV peptides

AU Gokulan, K.; Khare, S.; Rao, D. N.
CS Department of Biochemistry, All India Institute of Medical Sciences New Delhi, New Delhi, 110 029, India
SO Indian Journal of Clinical Biochemistry (1998), 13(2), 111-118
CODEN: IJCBEY, ISSN: 0970-1915
PB Association of Clinical Biochemists of India
DT Journal
LA English
RE.CNT 25
THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2002 ACS

AN 1995:996653 CAPLUS
DN 124:53725
TI Cellular immune response-specific antigens as vaccines for treatment of tumors and infections
AU Longenecker, B. Michael; Ding, Lei; Reddish, Mark A.; Koganly, Raghupathi Rao
PA Biomira, Inc., Can.
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9527505 A1 19951019 WO 1995-US4540 19950412
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA
RW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
PRAI AU 9522470 A1 19951030 AU 1995-22470 19950412
US 1994-229606 19940412
WO 1995-US4540 19950412

L17 ANSWER 6 OF 71 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1999222808 EMBASE

TI Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications.
 AU Baert F.J.; Rutgeerts P.R.
 CS P.R. Rutgeerts, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
 SO International Journal of Colorectal Disease, (1999) 14/1 (47-51).
 Refs: 29
 ISSN: 0179-1958 CODEN: IUCDE6
 CY Germany
 DT Journal, Article
 FS 005 General Pathology and Pathological Anatomy
 026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 048 Gastroenterology
 LA English
 SL English

L17 ANSWER 7 OF 71 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1993:500167 BIOSIS
 DN PREV199396124174
 TI Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide.
 AU Hoffman, Orleen A.; Olson, Eric J.; Limper, Andrew H. (1)
 CS (1) Thoracic Diseases, E-188 Mayo Clinic, Rochester, MN 55905 USA
 SO Immunology Letters, (1993) Vol. 37, No. 1, pp. 19-25.
 ISSN: 0165-2478.
 DT Article
 LA English

L17 ANSWER 8 OF 71 USPATFULL
 AN 1999:163694 USPATFULL
 TI Substituted 4-amino-7H-pyrimidino [2,3,-d]-pyrimidines as PTK inhibitors
 AU Calderwood, David J.; Nottingham, United Kingdom
 IN Johnston, David N.; Nottingham, United Kingdom
 RA Raftery, Paul; Nottingham, United Kingdom
 PA Twigg, Helen L.; Nottingham, United Kingdom
 Munschauser, Rainer; Shrewsbury, MA, United States
 Arnold, Lee; Westborough, MA, United States
 BASF Aktiengesellschaft, Rheinland-Pfalz, Germany, Federal Republic of (non-U.S. corporation)
 PI US 6001839 19991214
 AI US 1998-42702 19980317 (9)
 PRAI US 1997-40836P 19970319 (60)
 DT Utility
 FS Granted
 LN.CNT 2239
 INCL INCLM: 514/258.000
 INCLS: 544/280.000
 NCL NCLM: 514/265.100
 NCLS: 544/280.000
 IC [6]
 ICM: C07D487-04
 ICS: A61K031-505
 EXF 544/280; 514/258

L17 ANSWER 9 OF 71 USPATFULL
 AN 1999:160214 USPATFULL
 TI Immunoadhesins and methods of production and use thereof
 AU Csaky, Karl G.; Kensington, MD, United States
 IN Anglade, Eddy; Silver Spring, MD, United States

PA Sullivan, Daniel M.; Galtersburg, MD, United States
 LA Rochele, William; Galtersburg, MD, United States
 PI The United States of America, as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 AU US 5998598 19991207 (8)
 AI US 1997-814567 19970310 (8)
 DT Utility
 FS Granted
 LN.CNT 2608
 INCL INCLM: 536/023.400
 INCLS: 435/320.100; 514/044.000; 536/023.100; 536/023.530; 536/023.720;
 NCL NCLM: 536/024.100
 NCLS: 435/320.100; 536/023.100; 536/023.530; 536/023.720; 536/024.100
 IC [6]
 ICM: A61K048-00
 ICS: C07H021-04; C12N015-62; C12N015-13
 EXF 435/320.1; 514/44; 536/23.4; 536/23.5; 536/23.53; 536/23.72; 536/24.1; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 71 USPATFULL
 AN 1999:146760 USPATFULL
 TI Phosphorylated fusion proteins
 AU Pestka, Sidney; North Caldwell, NJ, United States
 IN PBL Biomedical Laboratories, New Brunswick, NJ, United States (U.S. corporation)
 PI US 5986061 19991116
 AI US 1995-482087 19950607 (8)
 RLI Continuation of Ser. No. US 1995-375112, filed on 19 Jan 1995 which is a continuation of Ser. No. US 1993-156875, filed on 23 Nov 1993, now abandoned which is a continuation of Ser. No. US 1988-264271, filed on 28 Oct 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2596
 INCL INCLM: 530/352.000
 INCLS: 435/069.510; 435/071.200; 435/069.700; 435/471.000; 435/325.000; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 536/023.520; 424/001.410; 424/001.490
 NCL NCLM: 530/352.000
 NCLS: 435/069.510; 435/069.700; 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.400; 536/023.500; 536/023.520
 IC [6]
 ICM: C07K014-56
 ICS: C07K014-565; C12N015-62
 EXF 530/351; 530/352; 435/69.51; 435/71.1; 435/71.2; 435/69.7; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471; 536/23.4; 536/23.5; 536/23.52; 935/11; 935/22; 935/27; 935/66; 935/72; 424/1.41; 424/1.49
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 71 USPATFULL
 AN 1999:117645 USPATFULL
 TI Products and processes for regulation of gene recombination
 AU Dreyfus, David H.; Denver, CO, United States
 IN Gelfand, Erwin W.; Englewood, CO, United States
 PA National Jewish Medical and Research Center, Denver, CO, United States (U.S. corporation)
 PI US 5958074 19990928
 AI US 1997-807332 19970228 (8)
 PRAI US 1996-12616P 19960301 (60)
 DT Utility
 FS Granted
 LN.CNT 2596
 INCL INCLM: 530/352.000
 INCLS: 435/069.510; 435/071.200; 435/069.700; 435/471.000; 435/325.000; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 536/023.520; 424/001.410; 424/001.490
 NCL NCLM: 530/352.000
 NCLS: 435/069.510; 435/069.700; 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.400; 536/023.500; 536/023.520
 IC [6]
 ICM: C07K014-56
 ICS: C07K014-565; C12N015-62
 EXF 530/351; 530/352; 435/69.51; 435/71.1; 435/71.2; 435/69.7; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471; 536/23.4; 536/23.5; 536/23.52; 935/11; 935/22; 935/27; 935/66; 935/72; 424/1.41; 424/1.49
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LN.CNT 2196
INCL INCLM: 530/300.000
INCIS: 530/324.000
NCL NCLM: 530/300.000
NCIS: 530/324.000
IC [6]
ICM: C07K014-00
EXF 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/330;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 71 USPTAFULL
AN 1999:117243 USPTAFULL
TI Methods and compositions for regulating T cell subsets by modulating
transcription factor activity
IN Glimcher, Laurie H., West Newton, MA, United States
PA Ho, I-Cheng, Newton, MA, United States
PI (U.S. corporation)
PI US 5958671
DT Utility
DT US 1996-636602
FS 19990928
FS 19960423 (8)
LN.CNT 2803
INCL INCLM: 435/004.000
INCIS: 435/006.000; 435/029.000; 435/375.000; 435/455.000
NCL NCLM: 435/004.000
NCIS: 435/006.000; 435/029.000; 435/375.000; 435/455.000
IC [6]
ICM: C12N001-02
EXF 435/4; 435/29; 435/6; 435/172.3; 435/375; 435/34-37; 435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 71 USPTAFULL
AN 1999:113365 USPTAFULL
TI Tuberculosis vaccine
IN Andersen, Peter, Bronshoj, Denmark
Andersen, Anne, Søborg, Denmark
Haslov, Kaare, Søborg, Denmark
Sorensen, Anne Lund, Bronshoj, Denmark
PA Statens Serum Institut, Copenhagen, Denmark (non-U.S. corporation)
PI US 5955077
PI US 1995-465640
PI US 1995-0605 (8)
R1 Continuation-in-part of Ser. No. US 1993-123182, filed on 20 Sep 1993,
now abandoned And Ser. No. WO 1994-DK273, filed on 1 Jul 1994
DT Utility
DT US 1994-023700
FS Granted
LN.CNT 2205
INCL INCLM: 424/184.100
INCIS: 424/185.100; 424/190.100; 424/234.100; 424/248.100; 435/069.300;
435/071.100; 435/325.000; 530/300.000; 530/327.000; 530/344.000;
530/350.000; 530/412.000; 536/023.700
NCL NCLM: 424/184.100
NCIS: 424/185.100; 424/190.100; 424/234.100; 424/248.100; 435/069.300;
435/071.100; 435/325.000; 530/300.000; 530/327.000; 530/344.000;
530/350.000; 530/412.000; 536/023.700
IC [6]
ICM: A61K039-00
EXF 530/350; 530/300; 530/327; 530/344; 530/412; 540/12; 424/184.1;
424/185.1; 424/190.1; 424/234.1; 424/248.1; 435/69.3; 435/71.1; 435/325;
536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 71 USPTAFULL
AN 1999:89000 USPTAFULL
TI Cyclic nucleotide phosphodiesterases
IN Au-Yang, Janice, Berkeley, CA, United States
Cocks, Benjamin G., Palo Alto, CA, United States
Coleman, Roger, Mountain View, CA, United States
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States
PA Fisher, Douglas A., Gpton, CT, United States
Fisher Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
corporation)
PI US 5932423
PI US 1997-974565
DT Continuation-in-part of Ser. No. US 1996-624663, filed on 25 Mar 1996,
now patented, Pat. No. US 5798246
DT Utility
DT US 1997-974565
FS Granted
LN.CNT 2750
INCL INCLM: 435/006.000
INCIS: 435/069.100; 435/320.100; 435/325.000; 435/348.000; 536/023.200;
536/023.500
NCL NCLM: 435/006.000
NCIS: 435/069.100; 435/320.100; 435/325.000; 435/348.000; 536/023.200;
536/023.500
IC [6]
ICM: C12N001-68
EXF 435/6; 435/69.1; 435/70.3; 435/71.1; 435/71.2; 435/252.3;
435/320.1; 435/325; 435/348; 536/23.1; 536/23.2; 536/23.5; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 71 USPTAFULL
AN 1999:81756 USPTAFULL
TI Expression vector systems and method of use
IN Schwartz, Robert J., Houston, TX, United States
Demayo, Franco J., Houston, TX, United States
PA Mayo, Bert W., Houston, TX, United States
Baylor College of Medicine, Houston, TX, United States (U.S.
corporation)
PI US 5925564
PI US 1995-472809
PI US 1995-0607 (8)
R1 Continuation-in-part of Ser. No. US 1994-209846, filed on 9 Mar 1994,
now patented, Pat. No. US 5756264 And a continuation-in-part of Ser. No.
US 1991-789919, filed on 6 Nov 1991, now patented, Pat. No. US 5298422
DT Utility
DT US 1991-789919
FS Granted
LN.CNT 2905
INCL INCLM: 435/325.000
INCIS: 435/320.100
NCL NCLM: 435/325.000
NCIS: 435/320.100
IC [6]
ICM: C12N005-16
EXF 435/320.1; 435/172.3; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 71 USPTAFULL
AN 1999:81543 USPTAFULL
TI Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and
ligand antibodies as therapeutic agents for the treatment of
immunological disease
IN Browning, Jeffrey L., Brookline, MA, United States
Browning, Christopher D., Beverly, MA, United States

PA Hochman, Paula S., Brookline, MA, United States
 Bogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5955351 19990720
 AI US 1995-505606 19950721 (8)
 DT Utility
 FS Granted
 INCL LN.CNT 1968
 INCLM: 424/143.100
 INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/808.000;
 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730;
 530/388.850; 530/389.200
 NCL NCLM: 424/143.100
 NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;
 530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850;
 530/389.200; 530/395.000
 IC [6]
 ICM: A61K039-395
 EXF ICS: A61K038-16; C07K016-00; C07K016-28
 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73;
 530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 71 USPTAFULL
 AN 1999-78600 USPTAFULL
 TI Cyclic GMP phosphodiesterase
 IN Fisher, Douglas A., Groton, CT, United States
 Gooding, Douglas H., Redwood City, CA, United States
 Streeter, David Gray, Boulder Creek, CA, United States
 Inocyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5922595 19990713
 AI US 1997-987466 19971209 (8)
 DT Utility
 FS Granted
 INCL LN.CNT 2391
 INCLM: 435/320.100
 INCLS: 435/069.100; 435/006.000; 536/023.100; 536/023.500; 530/350.000
 NCLM: 435/320.100
 NCLS: 435/006.000; 435/069.100; 530/350.000; 536/023.100; 536/023.500
 IC [6]
 ICM: C12N015-00
 EXF ICS: 530/350; 435/320.1; 435/69.1; 435/6; 536/23.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 71 USPTAFULL
 AN 1999-72572 USPTAFULL
 TI DNA transcription unit vaccines that protect against avian influenza
 IN viruses and methods of use thereof
 Webster, Robert, Memphis, TN, United States
 St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)
 PI US 5916879 19990629
 AI US 1996-747286 19961112 (8)
 DT Utility
 FS Granted
 INCL LN.CNT 1891
 INCLM: 514/044.000
 INCLS: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;
 424/816.000
 NCLM: 514/044.000
 NCLS: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;
 536/023.720
 IC [6]
 ICM: A61K048-00

EXF ICS: C12N015-87; C12N015-44
 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 71 USPTAFULL
 AN 1999-39934 USPTAFULL
 TI Treatment for insulin dependent diabetes
 IN Burly, Linda C., West Newton, MA, United States
 PI Bogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 588507 19990330
 AI US 1995-447118 19950322 (8)
 DT Continuation-in-part of Ser. No. US 1993-29330, filed on 9 Feb 1993, now abandoned
 FS Utility
 INCL LN.CNT 1914
 INCLM: 424/130.100
 INCLS: 424/133.100; 424/145.100; 424/152.100; 424/158.100; 424/172.100;
 514/002.000
 NCLM: 424/130.100
 NCLS: 424/133.100; 424/145.100; 424/152.100; 424/158.100; 424/172.100;
 514/002.000
 IC [6]
 ICM: A61K039-395
 EXF ICS: A01N037-18
 424/143.1; 424/130.1; 424/133.1; 424/145.1; 424/152.1; 424/158.1;
 424/172.1; 530/350; 514/2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 71 USPTAFULL
 AN 1999-33242 USPTAFULL
 TI Method to prevent transplant rejection
 IN Levy, Julia G., Vancouver, Canada
 Obochl, Modestus O. K., Vancouver, Canada
 PI QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)
 PI US 5882328 19990316
 AI US 1996-759318 19961202 (8)
 DT Continuation-in-part of Ser. No. US 1995-371707, filed on 13 Jan 1995, now abandoned
 FS Utility
 INCL LN.CNT 1461
 INCLM: 604/020.000
 INCLS: 604/049.000; 424/810.000; 128/898.000
 NCLM: 604/020.000
 NCLS: 128/898.000; 424/810.000; 604/500.000
 IC [6]
 ICM: A61M001-30
 EXF ICS: 161M031-00
 604/19; 604/20; 604/48; 604/49; 514/885; 530/388.7; 530/388.73;
 530/388.75; 530/388.8; 530/388.85; 424/810; 424/140.1; 128/898
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 71 USPTAFULL
 AN 1999-24311 USPTAFULL
 TI Vaccine for enhanced production of IgA antibodies
 IN Mond, James J., Jerusalem, Israel
 Snapper, Clifford M., Potomac, MD, United States
 Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
 PI US 5874085 19990223
 AI US 1995-400322 19950308 (8)
 DT Continuation-in-part of Ser. No. US 1994-315492, filed on 30 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US

1993-150510, filed on 10 Nov 1993

DT Utility
FS Granted
LN.CNT 999
INCL INCLM: 424/195.110; 424/193.100; 424/194.100; 424/278.100; 424/085.200;
INCL INCLM: 424/184.100; 424/197.110
NCL NCLM: 424/195.110
NCLM: 424/085.400; 424/085.400; 424/184.100; 424/193.100; 424/194.100;
NCLM: 424/085.200; 424/278.100
IC [6]
ICM: A61K039-00
EXF ICS: A61K038-18; A61K038-19; A61K039-02
424/184.1; 424/278.4; 424/193.1; 424/85.2; 514/2; 514/8; 514/885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 71 USPTAFULL
AN 1993:21711 USPTAFULL
TI CXG chemokines as regulators of angiogenesis
IN Strieter, Robert M., Ann Arbor, MI, United States
Polymerini, Peter J., Ann Arbor, MI, United States
Kunkel, Steven L., Ann Arbor, MI, United States
PA The Regent of the University of Michigan, Ann Arbor, MI, United States
PI (U.S. corporation)
AI US 5871723 19930216
DT US 1993-468819 19930606 (8)
FS Utility
LN.CNT 6055
INCL INCLM: 424/085.100
INCLM: 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 424/085.100
NCLM: 514/002.000; 514/008.000; 514/012.000
IC [6]
ICM: A61K038-19
EXF 424/85.1; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 71 USPTAFULL
AN 1998:157496 USPTAFULL
TI CD40 coding sequences
IN Seed, Brian, Boston, MA, United States
Allen, Janet, Glasgow, Scotland
Aruffo, Alejandro, Edmonds, WA, United States
Camerini, David, Charlottesville, VA, United States
Lautner, Leander, Gladenbach, Germany, Federal Republic of
Oquendo, Carmen, Gladenbach, Germany, Federal Republic of
Simmons, David, Headington, United Kingdom
Stamenkovic, Ivan, Winchester, MA, United States
Stangelin, Siegfried, Epstein, Germany, Federal Republic of
Amiot, Martine, Nantes, France
PA The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)
PI US 5849898 19981215
AI US 1995-485447 19950607 (8)
R1 Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-988809, filed on 23 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned

DT Utility
FS Granted

LN.CNT 3541
INCL INCLM: 536/023.500
INCLM: 435/069.100; 435/257.300; 435/320.100
NCL NCLM: 536/023.500
NCLM: 435/069.100; 435/257.300; 435/320.100
IC [6]
ICM: C12N015-12
EXF 536/23.5; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 24 OF 71 USPTAFULL
AN 1998:157145 USPTAFULL
TI Method for making unclipped HIV envelope protein
IN Bertram, Phillip W., Portola Valley, CA, United States
Fendly, Brian M., Half Moon Bay, CA, United States
Gregory, Timothy J., Hillsborough, CA, United States
Worm, Florian M., Foster City, CA, United States
PA Genetech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 5849533 19981215
AI US 1997-802361 19970219 (8)
R1 Continuation of Ser. No. US 1994-226162, filed on 11 Apr 1994, now patented, Pat. No. US 5674984 which is a division of Ser. No. US 1993-101669, filed on 2 Aug 1993, now abandoned which is a continuation of Ser. No. US 1992-834735, filed on 13 Feb 1992, now abandoned which is a division of Ser. No. US 1990-504785, filed on 3 Apr 1990, now abandoned

DT Utility
FS Granted
LN.CNT 2639
INCL INCLM: 435/069.300
INCLM: 424/188.100; 424/208.100; 435/172.300; 530/412.000; 530/413.000
NCL NCLM: 435/069.300
NCLM: 424/188.100; 424/208.100; 530/412.000; 530/413.000
IC [6]
ICM: C12P021-00
EXF ICS: C12P021-02
424/148.1; 424/160.1; 424/188.1; 424/208.1; 435/69.3; 435/172.3;
435/325; 435/352; 435/358; 435/362; 435/320.1; 530/412; 530/413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 71 USPTAFULL
AN 1998:154116 USPTAFULL
TI Fungal Protease
IN Buxton, Frank, Holderstedeijweg 32, 4132 Murtenz, Switzerland
Hinnen, Albert, Am Planetarium 32, 07743 Jena, Germany, Federal Republic of
PA Visser, Jacob, Hinkeloordeweg 5, 6703 CK Wengeningen, Netherlands
PI US 5846802 19981208
AI US 1994-225488 19940408 (8)
R1 Continuation-in-part of Ser. No. US 1993-47214, filed on 13 Apr 1993, now abandoned
PRAI GB 1993-810281 19930415
GB 1993-5097 19930312
DT Utility
FS Granted
LN.CNT 2639
INCL INCLM: 435/225.000
INCLM: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;
INCLM: 435/014.000; 435/028.000; 435/068.000; 536/023.200
NCL NCLM: 435/225.000
NCLM: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;
NCLM: 536/023.200
IC [6]
ICM: C12N015-57

ICS: C12N015-80; C12N019-34; C12N009-12
 EXF 435/225; 435/69.1; 435/172.3; 435/254.3; 435/320.1;
 536/252.3; 536/23.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 71 USPTFULL
 AN 1998:133867; USPTFULL
 TI Preparation and use of viral vectors for mixed envelope protein
 IN Immunogenic composition against human immunodeficiency viruses
 Stobod, Karen, Memphis, TN, United States
 St. Jude Children's Research Hospital, Memphis, TN, United States (U.S.
 corporation)
 PI US 5846546 19981208
 AI US 1997-788815 19970123 (8)
 RLI Continuation-in-part of Ser. No. US 1996-590288, filed on 23 Jan 1996,
 Utility
 DT Utility
 FS Granted
 LN.CNT 2393
 INCL INCLM: 424/202.100 424/208.100; 514/044.000; 536/023.720
 NCL INCLM: 424/191.100; 424/202.1; 514/44; 536/23.72
 NCL NCLM: 424/199.100; 424/208.100; 514/044.000; 536/023.720
 IC [6]
 ICM: A61K039-295
 EXF ICS: A61K039-12; A61K039-21; A01N043-04
 424/199.1; 424/202.1; 424/208.1; 514/44; 536/23.72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 71 USPTFULL
 AN 1998:150739 USPTFULL
 TI Alphavirus vector constructs
 IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 Belli, Barbara A., San Diego, CA, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 5843723 19981201
 AI US 1996-739167 19961030 (8)
 RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is a
 Continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,
 now abandoned which is a continuation-in-part of Ser. No. US
 1994-348472, filed on 30 Nov 1994, now abandoned which is a
 continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,
 now abandoned which is a continuation-in-part of Ser. No. US
 1993-122791, filed on 15 Sep 1993, now abandoned
 Utility
 DT Utility
 FS Granted
 LN.CNT 10318
 INCL INCLM: 435/069.300
 INCLM: 435/320.100; 435/325.000; 435/235.100
 NCL NCLM: 435/069.300
 NCLM: 435/235.100; 435/320.100; 435/325.000
 IC [6]
 ICM: C12P021-02
 EXF ICS: C12N015-63; C12N005-10
 435/320.1; 435/325; 435/69.3; 435/235.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 71 USPTFULL

AN 1998:134881 USPTFULL
 TI Cloning vector, polylinker and methods
 IN Seed, Brian, Boston, MA, United States
 Aruffo, Alejandro, Edmonds, WA, United States
 The General Hospital Corporation, Charlestown, MA, United States (U.S.
 corporation)
 PI US 5830731 19981103
 AI US 1997-861205 19970521 (8)
 RLI Continuation of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a
 Continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990,
 now abandoned which is a continuation of Ser. No. US 1989-359076, filed
 on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser.
 No. US 1988-160416, filed on 25 Feb 1988, now abandoned
 Utility
 DT Utility
 FS Granted
 LN.CNT 3587
 INCL INCLM: 435/172.300
 INCLM: 435/252.300; 435/320.100; 536/024.200
 NCL NCLM: 435/091.410
 NCLM: 435/252.300; 435/320.100; 536/024.200
 IC [6]
 ICM: C12N015-66
 EXF 435/252.7; 435/320.1; 435/172.3; 536/24.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 71 USPTFULL
 AN 1998:134627 USPTFULL
 TI Yeast-based delivery vehicles
 IN Duke, Richard C., Denver, CO, United States
 Franzusoff, Alex, Boulder, CO, United States
 Bellgrau, Donald, Denver, CO, United States
 University Technology Corporation, Boulder, CO, United States (U.S.
 corporation)
 PI US 5830463 19981103
 AI US 1994-340185 19941115 (8)
 RLI Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now
 patented, Pat. No. US 5413914
 DT Utility
 FS Granted
 LN.CNT 1929
 INCL INCLM: 424/093.510
 INCLM: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300;
 435/069.100
 NCL NCLM: 424/093.510
 NCLM: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000
 IC [6]
 ICM: C12N015-00
 EXF ICS: C12N015-09; A61K048-00
 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31;
 514/44; 935/62; 935/52; 935/55; 935/56; 935/57; 935/34; 935/32;
 424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 71 USPTFULL
 AN 1998:119004 USPTFULL
 TI Eukaryotic layered vector initiation systems
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Santa Fe, CA, United
 States 92067
 Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States
 92109
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024
 Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117
 PI US 5814482 19980929
 AI US 1996-739158 19961030 (8)

RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-384872, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 Utility
 FS Granted
 IN CNT 10431
 INCLM: 435/069.300
 INCLS: 435/320.100; 536/023.100; 536/024.100
 NCLM: 435/069.300
 NCLS: 435/320.100; 536/023.100; 536/024.100
 IC [6]
 ICM: C12P021-00
 ICS: C12N015-86; C07H021-04
 EXF 435/69.3; 435/320.1; 536/23.1; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 31 OF 71 USPTAFULL
 AN 1998:11645 USPTAFULL
 TI Compositions for conferring immunogenicity to a substance and uses thereof
 IN Stanton, G. John, Texas City, TX, United States
 Hughes, Jr., Thomas K., Galveston, TX, United States
 Smith, Eric M., Galveston, TX, United States
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
 PA US 5807552 19980915
 PI US 1995-511662 19950804 (8)
 AI Utility
 DT Granted
 FS
 LN CNT 2678
 INCLM: 424/188.100
 INCLS: 424/184.100; 424/186.100; 530/324.000; 530/333.000; 530/826.000; 514/002.000; 514/012.000; 514/934.000; 535/005.000; 535/974.000
 NCLM: 424/188.100; 424/186.100; 514/002.000; 514/012.000; 514/934.000
 NCLS: 424/184.100; 424/186.100; 514/002.000; 514/012.000; 514/934.000; 530/324.000; 530/333.000; 530/826.000
 IC [6]
 ICM: A61K039-21
 EXF 530/324-331; 530/333; 530/334; 530/826; 435/5; 435/974; 424/184.1; 424/186.1; 424/188.1; 514/2; 514/12-19; 514/934
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 32 OF 71 USPTAFULL
 AN 1998:108036 USPTAFULL
 TI Recombinant canine herpesviruses
 IN Haanes, Elizabeth J., Berchoud, CO, United States
 Frank, Rexann S., Wellington, CO, United States
 Heeka Corporation, Ft. Collins, CO, United States (U.S. corporation)
 PA US 5804197 19980908
 PI US 1996-680726 19960712 (8)
 AI US 1996-680726 19960712 (8)
 DT Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996
 FS Utility
 LN CNT 5536
 INCLM: 424/229.100
 INCLS: 424/199.100; 435/235.100; 435/320.100
 NCLM: 424/229.100
 NCLS: 424/199.100; 435/235.100; 435/320.100
 IC [6]
 ICM: A61K039-245

ICS: A61K039-00; C12N007-01; C12N015-00
 EXF 424/229.1; 424/199.1; 435/235.1; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 33 OF 71 USPTAFULL
 AN 1998:101537 USPTAFULL
 TI Cyclic nucleotide phosphodiesterase
 IN Au-Young, Janice, Berkeley, CA, United States
 Cocks, Benjamin Graeme, Palo Alto, CA, United States
 Coleman, Roger, Mountain View, CA, United States
 Selhammer, Jeffrey J., Los Altos Hills, CA, United States
 Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
 PA US 5798246 19980825
 PI US 1996-624663 19960325 (8)
 AI Utility
 DT Granted
 FS
 LN CNT 1820
 INCLM: 435/196.000
 INCLS: 435/172.300; 435/320.100; 435/325.000; 536/023.200; 536/023.500
 NCLM: 435/196.000
 NCLS: 435/320.100; 435/325.000; 536/023.200; 536/023.500
 IC [6]
 ICM: C12N009-18
 ICS: C12N015-12; C12N015-52; C12N015-85
 EXF 536/23.2; 536/23.5; 435/325; 435/320.1; 435/69.1; 435/172.3; 435/197
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 34 OF 71 USPTAFULL
 AN 1998:98981 USPTAFULL
 TI Lymphotoxin-beta and lymphotoxin-beta complexes
 IN Browning, Jeffrey, Brookline, MA, United States
 Ware, Carl F., Riverside, CA, United States
 Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PA US 5795964 19980818
 PI US 1995-467070 19950606 (8)
 AI US 1995-467070 19950606 (8)
 RLI Division of Ser. No. US 1994-222614, filed on 1 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned
 Utility
 DT Granted
 FS
 LN CNT 2597
 INCLM: 530/351.000
 INCLS: 530/324.000; 530/350.000; 514/012.000; 536/023.400; 536/023.500
 NCLM: 530/351.000
 NCLS: 530/324.000; 530/350.000; 536/023.400; 536/023.500
 IC [6]
 ICM: C07K014-46
 ICS: C07K014-52; C07K014-435
 EXF 530/324; 530/350; 530/351; 514/12; 536/23.4; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 35 OF 71 USPTAFULL
 AN 1998:98884 USPTAFULL
 TI Analogs for specific oligosaccharide-protein interactions and uses therefor
 IN Witt, Daniel P., Hamilton, MA, United States
 Herlitz, Jr., Walter C., Beverly, MA, United States
 PA Repligen Corporation, Needham, MA, United States (U.S. corporation)
 PI US 5795860 19980818
 AI US 1994-202989 19940228 (8)
 RLI Continuation-in-part of Ser. No. US 1993-24558, filed on 1 Mar 1993, now abandoned

DT Utility
FS Granted
LN.CNT 2449
INCL INCLM: 514/012.000; 514/054.000; 514/062.000; 530/350.000; 530/359.000;
INCLM: 514/002.000; 536/055.200
NCLM: 514/012.000
NCLM: 514/002.000; 514/054.000; 514/062.000; 530/350.000; 530/359.000;
NCLM: 514/002.000; 536/055.200
IC [6]
ICM: A01N037-18
ICS: A61K031-70
514/54; 514/56; 514/2; 514/12; 514/62; 536/55.1; 530/55.2; 530/350;
530/359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 71 USPTAFUL
AN 1998:91872 USPTAFUL
TI Alphavirus structural protein expression cassettes
IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
Polo, John M., San Diego, CA, United States
Ibanez, Carlos E., San Diego, CA, United States
Chang, Stephen M. W., San Diego, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
Driver, David A., San Diego, CA, United States
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5789245 19961030 (8)
US 1996-741881
Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a
continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,
now abandoned which is a continuation-in-part of Ser. No. US
1994-348472, filed on 30 Nov 1994, now abandoned which is a
continuation-in-part of Ser. No. US 1994-188450, filed on 18 Feb 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1993-122791, filed on 15 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 10270
INCL INCLM: 435/320.100; 435/325.000; 536/023.720
INCLM: 435/691.000; 435/320.100
NCLM: 435/320.100
NCLM: 435/069.100; 435/325.000; 536/023.720
IC [6]
ICM: C12N015-63
ICS: C12N015-40; C12N005-10; C12P021-02
435/320.1; 435/69.1; 435/325. 536/23.72
EXF 435/320.1; 435/69.1; 435/325. 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 71 USPTAFUL
AN 1998:68822 USPTAFUL
TI Cysteine-pegylated proteins
IN Braxton, Scott M., San Mateo, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
corporation)
PI US 5766897 19980616
US 1995-427100 19950421 (8)
Continuation-in-part of Ser. No. US 1993-144758, filed on 29 Oct 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1992-924294, filed on 3 Aug 1992, now patented. Pat. No. US 5457090
which is a continuation of Ser. No. US 1990-542484, filed on 21 Jun
1990, now patented, Pat. No. US 5187089, issued on 16 Feb 1993
DT Utility
FS Granted
LN.CNT 2765

INCL INCLM: 435/172.100
INCLM: 435/188.000; 435/212.000; 435/219.000
NCLM: 435/463.000
NCLM: 435/188.000; 435/212.000; 435/219.000
IC [6]
ICM: C12N015-00
ICS: C12N009-96; C12N009-48; C12N009-50
514/12; 530/350; 435/69.2; 435/188; 435/172.1; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 71 USPTAFUL
AN 1998:57762 USPTAFUL
TI Aspergillus niger vacuolar aspartyl protease
IN Buxton, Frank, Mulfenz, Switzerland
Jara, Gabor, Oberwil, Switzerland
Vlaser, Jacob, Wageningen, Netherlands
Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5756338 19980526
US 1996-731045 19961008 (8)
Division of Ser. No. US 1994-328314, filed on 24 Oct 1994, now patented,
Pat. No. US 5674728, issued on 7 Oct 1997
PRAI GB 1993-810764 19931103
DT Utility
FS Granted
LN.CNT 1957
INCL INCLM: 435/219.000
INCLM: 435/254.300; 536/023.200
NCLM: 435/219.000
NCLM: 435/254.300; 536/023.200
IC [6]
ICM: C12N009-62
ICS: C12N015-57; C12N015-63; C12N015-80
435/219; 435/254.3; 435/2; 536/23.2
EXF 435/219; 435/254.3; 435/2; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 71 USPTAFUL
AN 1998:57690 USPTAFUL
TI Expression vector systems and method of use
IN Schwartz, Robert J., Houston, TX, United States
Demayo, Franco J., Houston, TX, United States
O'Walley, Bert W., Houston, TX, United States
Baylor College of Medicine, Houston, TX, United States (U.S.
corporation)
PI US 5756264 19980526
US 1994-209846 19940309 (8)
Continuation-in-part of Ser. No. US 1991-789919, filed on 6 Nov 1991,
now patented, Pat. No. US 5298422
DT Utility
FS Granted
LN.CNT 2798
INCL INCLM: 435/320.100
INCLM: 435/172.300; 435/252.300; 536/024.100
NCLM: 424/093.200
NCLM: 424/093.200
NCLM: 435/349.000; 435/455.000; 435/465.000; 514/044.000; 536/024.100
IC [6]
ICM: C12N005-10
ICS: C12N015-63
435/69.1; 435/172.3; 476/242.3; 436/32.1; 536/24.1
EXF 435/69.1; 435/172.3; 476/242.3; 436/32.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 71 USPTAFUL
AN 1998:54490 USPTAFUL
TI Recombinant canine herpesviruses

EXF 435/320.1: 435/6; 435/69.1; 435/112.3; 435/243; 435/252.1; 514/44;
 935/62; 935/66; 935/69; 935/70; 935/71; 935/72; 935/73; 935/74; 935/72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 43 OF 71 USPATFULL
 AN 1998:27762 USPATFULL
 TI Methods and compositions incorporating:IP-10
 IN Sarris, Andreas H., Houston, TX, United States
 Broxmeyer, Hal R., Indianapolis, IN, United States
 Ravech, Jeff V., New York, NY, United States
 PA Board of Regents, The University of Texas System, Austin, TX, United
 States (U.S. corporation)
 Indiana University Foundation, Bloomington, IN, United States (U.S.
 corporation)
 Sloan-Kettering Institute for Cancer Research, New York, NY, United
 States (U.S. corporation)
 PI US 5728377 19980317
 AI US 1993-94851 19930720 (8)
 DT Utility
 FS Granted
 LN.CNT 1630
 INCL INCLM: 424/085.100
 NCL INCLS: 435/069.500; 530/351.000
 NCLM: 424/085.100
 NCLS: 435/069.500; 530/351.000
 IC [6]
 ICM: A61K045-05
 EXF 424/85.1: 435/69.5; 530/351; 935/13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 44 OF 71 USPATFULL
 AN 97:117676 USPATFULL
 TI Polyspecific immunocomposites and antibody composites for targeting the
 IN multidrug resistant phenotype
 Goldenberg, David M., Menham, NJ, United States
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
 PI US 5698178 19971216
 AI US 1996-629387 19960408 (8)
 RI1 Division of Ser. No. US 1994-286430, filed on 5 Aug 1994
 DT Utility
 FS Granted
 LN.CNT 2203
 INCL INCLM: 424/001.490
 NCL INCLS: 424/009.341; 424/009.600; 424/001.530
 NCLM: 424/001.490
 NCLS: 424/001.530; 424/009.341; 424/009.600
 IC [6]
 ICM: A61K049-00
 EXF 424/9.341; 424/1.49; 424/9.6; 424/1.53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 45 OF 71 USPATFULL
 AN 97:104602 USPATFULL
 TI Polyspecific immunocomposites and antibody composites for targeting the
 IN multidrug resistant phenotype
 Goldenberg, David M., Menham, NJ, United States
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
 PI US 5686578 19971111
 AI US 1994-286430 19940805 (8)
 DT Utility
 FS Granted
 LN.CNT 2133
 INCL INCLM: 530/387.300
 NCL INCLS: 530/391.100; 530/391.900; 530/389.700; 530/389.500; 530/388.800;

NCL INCLM: 530/388.850; 530/389.100; 530/388.200; 530/388.400
 NCLM: 530/387.300
 NCLM: 530/388.200; 530/388.400; 530/388.800; 530/388.850; 530/389.100;
 530/389.500; 530/389.700; 530/391.100; 530/391.900
 IC [61]
 ICM: C07K016-00
 ICS: C07K016-18; C07K016-28; C07K016-12
 530/387.3; 530/391.1-391.9; 530/389.7; 530/389.5; 530/388.8; 530/388.85;
 530/389.1; 530/388.2; 530/388.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 46 OF 71 USPTFULT
 AN 97:91639 USPTFULT
 TI Method for isolation of unclipped HIV envelope protein
 IN Bernan, Phillip W., Potola Valley, CA, United States
 Gregory, Brian M., Half Moon Bay, CA, United States
 Gregory, Timothy J., Hillsborough, CA, United States
 Warm, Florian M., Foster City, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5674984 19971007
 AI US 1994-226162 19940411 (8)
 RLI Division of Ser. No. US 1993-101669, filed on 2 Aug 1993, now abandoned
 which is a continuation of Ser. No. US 1992-834735, filed on 13 Feb
 1992, now abandoned which is a division of Ser. No. US 1990-504785,
 filed on 3 Apr 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2652
 INCL INCLM: 530/413.000
 INCLM: 530/388.350; 530/412.000
 NCLM: 530/413.000
 NCLM: 530/388.350; 530/412.000
 IC [6]
 ICM: C07K001-22
 424/148.1; 424/160.1; 424/188.1; 424/208.1; 530/388.35; 530/412; 530/413
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 47 OF 71 USPTFULT
 AN 97:91390 USPTFULT
 TI Aspergillus niger vacuolar aspartyl protease
 IN Buxton, Frank, Miltenz, Switzerland
 Jarai, Gabor, Oberwill, Switzerland
 Visser, Jacob, Wageningen, Netherlands
 PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
 PI US 5674728 19971007
 AI US 1994-328314 19941024 (8)
 PRAI EP 1993-810764 19931103
 DT Utility
 FS Granted
 LN.CNT 2018
 INCL INCLM: 435/225.000
 INCLM: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/172.300;
 435/320.100; 536/023.200
 NCLM: 435/225.000
 NCLM: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/320.100;
 435/477.000; 435/488.000; 536/023.200
 IC [61]
 ICM: C12N015-58
 ICS: C12N015-80; C12N015-90; C12N009-62
 435/219; 435/223; 435/225; 435/252.3; 435/254.11; 435/254.3; 435/172.3;
 435/320.1; 435/69.1; 536/23.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 48 OF 71 USPTFULT
 AN 97:86585 USPTFULT
 TI Method to enhance permeability of the blood/brain blood/nerve barriers to
 IN therapeutic agents
 Poduio, Joseph F., 5719 St. Mary's Dr. NW, Rochester, MN, United States
 55901
 PA Curran, Geoffrey L., 629 23rd St. NE, Rochester, MN, United States
 55906
 PRAI Poduio, Joseph F., Rochester, MN, United States (U.S. individual)
 AI US 5670477 19970923
 DT US 1995-425376 19950420 (8)
 FS Utility
 LN.CNT 1978
 INCL INCLM: 514/002.000
 NCLM: 514/002.000
 IC [6]
 ICM: A61K023-02
 514/2
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 49 OF 71 USPTFULT
 AN 97:86267 USPTFULT
 TI Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical
 IN preparations and therapeutic uses thereof
 Browning, Jeffrey, Brookline, MA, United States
 Ware, Carl F., Riverside, CA, United States
 PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 The University of California, Oakland, CA, United States (U.S. corporation)
 PI US 5670149 19970923
 AI US 1995-476489 19950606 (8)
 RLI Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now
 abandoned which is a continuation-in-part of Ser. No. US 1990-544862,
 filed on 27 Jun 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2504
 INCL INCLM: 424/130.100
 INCLM: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;
 424/158.100; 435/069.500; 530/388.220; 530/388.240
 NCLM: 424/130.100
 NCLM: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;
 424/158.100; 435/069.500; 530/388.220; 530/388.240
 IC [61]
 ICM: A61K039-395
 435/69.5; 435/172.1; 435/320.1; 530/388.22; 530/388.24; 424/130.1;
 424/133.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L17 ANSWER 50 OF 71 USPTFULT
 AN 97:75989 USPTFULT
 TI Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical
 IN preparations and therapeutic uses thereof
 Browning, Jeffrey, Brookline, MA, United States
 Ware, Carl F., Riverside, CA, United States
 PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 The University of California, Oakland, CA, United States (U.S. corporation)
 PI US 5661004 19970826
 AI US 1995-484272 19950607 (8)
 RLI Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now
 abandoned which is a continuation of Ser. No. US 1992-990304, filed on 4
 Dec 1992, now abandoned which is a continuation of Ser. No. US

1990-544862, filed on 27 Jun 1990, now abandoned

Oncostatin

DT Utility

FS Granted

LN.CNT 2578

INCL INCLM: 435/069.100

NCL INCLM: 435/069.100

IC ICM: C12N015-00

EXF ICS: C12N015-11; C12N015-85

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 51 OF 71 USPTFULT

AN 97:47501 USPTFULT

TI Peptides that bind IL-2 receptors

IN Barrett, Ronald W., Sunnyvale, CA, United States

Chernov-Rogan, Tania, Belmont, CA, United States

Davis, Ann M., Mountain View, CA, United States

Allymax Technologies, N.V., Curacao, Netherlands Antilles (non-U.S. corporation)

PI US 5635597

AI US 1994-250789

DT Utility

FS Granted

LN.CNT 2025

INCL INCLM: 530/327.000

NCL INCLM: 530/327.000

IC ICM: C07K007-08

EXF 530/300; 530/327; 530/350; 530/351

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 52 OF 71 USPTFULT

AN 97:47265 USPTFULT

TI Anti-concoimmunin-M antibodies and uses thereof

IN Packard, Beverly, Rockville, MD, United States

Komoriya, Akira, Rockville, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5635356

AI US 1994-218023

DT Utility

FS Granted

LN.CNT 2403

INCL INCLM: 435/007.100

NCL INCLM: 435/007.100

IC ICM: C07K016-24

EXF ICS: C07K014-52; C12P021-08; G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 53 OF 71 USPTFULT

AN 97:29374 USPTFULT

=> d his

(FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFULL' ENTERED AT 10:34:58 ON 25 APR 2002

L1 246870 S FUSION PROTEIN? OR CHIMER?
L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1
L3 27059 S L1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN
L4 208008 S L1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN
L5 10 S PROLACTIN AGONIST
L6 80 S PROLACTIN ANTAGONIST
L7 55 S L6 NOT PY=>2000
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)
L9 4 S L6 AND L1
L10 1358 S IMMUNOMODULATOR? AND L1
L11 1124 DUP REM L10 (234 DUPLICATES REMOVED)
L12 509 S L11 NOT PY=>2000
L13 100 S L12 AND INTERLEUKIN 2
L14 8 S L12 AND INTERLEUKIN 12
L15 70916 S L12 AND INTERFERON GAMMA OR GAMMA INTERFERON
L16 76 S L12 AND GAMMA INTERFERON
L17 71 S L12 AND INTERFERON GAMMA

=> d 116 1-76

L16 ANSWER 1 OF 76 MEDLINE
AN 97184551 MEDLINE
DN 97184551 Pubmed ID: 9032353
TI The hepatitis B virus core and e antigens elicit different Th cell
subsets: antigen structure can affect Th cell phenotype.
AU Milich D R; Schodel F; Hughes J L; Jones J E; Peterson D L
CS Department of Molecular Biology, The Scripps Research Institute, La Jolla,
California 92037, USA.
NC A120720 (NLAID)
SO JOURNAL OF VIROLOGY, (1997 Mar) 71 (3): 2192-201.
JN Journal code: KCV; 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199703
ED Entered STN: 19970327
Last Updated on STN: 19970327
Entered Medline: 19970318

L16 ANSWER 2 OF 76 MEDLINE
AN 92330820 MEDLINE
DN 92330820 Pubmed ID: 1628125
TI The role of recombinant cytokines and other immunomodulators on
engraftment following allogeneic bone marrow transplantation in mice.
AU Biedert A; Weiss L; Slavin S
CS Department of Bone Marrow Transplantation, Hadassah University Hospital,
Jerusalem, Israel.
SO BONE MARROW TRANSPLANTATION, (1992 Jun) 9 (6): 421-6.
JN Journal code: BON; 8702459. ISSN: 0268-3369.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199208
ED Entered STN: 19920904
Last Updated on STN: 19920904
Entered Medline: 19920820

L16 ANSWER 3 OF 76 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 1999222808 EMBASE
TI Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects,
indications.

CS P.R. Rutgeerts, Department of Gastroenterology, University Hospital
Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
AU Baert F.; Rutgeerts P.R.
SO International Journal of Colorectal Disease, (1999) 14(1) (47-51).
Refs: 29

ISSN: 0179-1958 CODEN: IJCD66

CY Germany
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
LA English
SL English

L16 ANSWER 4 OF 76 USPATFULL

AN 1999:159473 USPATFULL
TI Method and compositions for solubilization and stabilization of
polypeptides, especially proteins
IN Rubinfeld, Joseph; Danville, CA, United States
Stern, Warren; Gainesville, FL, United States
Wong, Gregory J.; San Leandro, CA, United States
Chilton Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5997856 19991207
AI US 1989-373928 19890629 (7)
RI Continuation-in-part of Ser. No. US 1988-253720, filed on 5 Oct 1988,
now abandoned
DT Utility
FS Granted
IN.CNT 1523
INCL INCLM: 424/085.200
NCL INCLM: 514/002.000
NCLM: 424/085.200
NCLM: 514/002.000
IC ICM: A61K038-20
ICS: A61K047-26
424/85.2; 514/2; 514/12; 514/21

EXF 424/85.2; 514/2; 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 76 USPATFULL

AN 1999:154818 USPATFULL
TI Method of treatment using electroporation mediated delivery of drugs and
genes
IN Dev, Subhendu B.; San Diego, CA, United States
Hofmann, Gunter A.; San Diego, CA, United States
Genetronics, Inc.; San Diego, CA, United States (U.S. corporation)
PA US 5993434 19991130
PI US 1995-537265 19950929 (8)
RI Continuation-in-part of Ser. No. US 1995-467566, filed on 6 Jun 1995,
now patented, Pat. No. US 5702359, which is a continuation-in-part of
Ser. No. US 1993-42039, filed on 1 Apr 1993, now patented, Pat. No. US
5439440
DT Utility

FS Granted
 LN.CNT 842
 INCL INCLM: 604/501.000
 INCLM: 604/020.000; 604/021.000
 NCL INCLM: 604/501.000
 NCLM: 604/020.000; 604/021.000
 IC [6]
 ICM: A61M031-00
 EXF 604/20-21; 604/49; 604/51; 604/501; 607/115-116; 435/173.6
 L16 ANSWER 6 OF 76 USPTAFULL
 AN 1999:146760 USPTAFULL
 TI Phosphorylated fusion proteins
 IN Pestka, Sidney, North Caldwell, NJ, United States
 PA PBL Biomedical Laboratories, New Brunswick, NJ, United States (U.S. corporation)
 PI US 5986061 19991116
 AI US 1995-482087 19950607 (8)
 RLI Continuation of Ser. No. US 1995-375112, filed on 19 Jan 1995 which is a continuation of Ser. No. US 1993-156875, filed on 23 Nov 1993, now abandoned which is a continuation of Ser. No. US 1988-264271, filed on 28 Oct 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2596
 INCL INCLM: 530/352.000
 INCLM: 435/069.510; 435/071.200; 435/069.700; 435/471.000; 435/325.000; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 536/023.520; 424/001.410; 424/001.490
 NCL INCLM: 530/352.000
 NCLM: 435/069.510; 435/069.700; 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.400; 536/023.500; 536/023.520
 IC [6]
 ICM: C07K014-56
 ICS: C07K014-565; C12N015-62
 EXF 530/331; 530/352; 435/69.51; 435/71.1; 435/71.2; 435/69.7; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471.0; 536/23.4; 536/23.5; 536/23.52; 935/11; 935/22; 935/27; 935/66; 935/72; 424/1.41; 424/1.49
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 7 OF 76 USPTAFULL
 AN 1999:137464 USPTAFULL
 TI Monoclonal antibody 1A7 and related polypeptides
 IN Chatterjee, Malaya, Lexington, KY, United States
 PA Foon, Kenneth A., Lexington, KY, United States
 PA Chatterjee, Sunil K., Lexington, KY, United States
 PA The Board of Trustees of the University of Kentucky, Lexington, KY, United States (U.S. corporation)
 PI US 5977316 19991102
 AI US 1996-591196 19960116 (8)
 RLI Continuation-in-part of Ser. No. US 1995-372676, filed on 17 Jan 1995, now patented, Pat. No. US 5612030
 DT Utility
 FS Granted
 LN.CNT 4578
 INCL INCLM: 530/387.200
 INCLM: 530/387.300; 530/387.700; 424/131.100; 424/133.300; 424/138.100
 NCL INCLM: 530/387.200
 NCLM: 424/131.100; 424/133.100; 424/138.100; 530/387.300; 530/387.700
 IC [6]
 ICM: A61K039-395
 EXF 530/387.2; 530/387.3; 530/387.7; 424/131.1; 424/133.3; 424/138.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 76 USPTAFULL
 AN 1999:128418 USPTAFULL
 TI Nuclear cyclophilin
 IN Wang, Bruce, 1123 Banyan Way, Pacifica, CA, United States 94044
 IN Payan, Donald, 24 Windsor Dr., Hillsborough, CA, United States 94010
 IN Fisher, Joseph, 1035 S. Van Ness Ave., Apt. D, San Francisco, CA, United States 94110
 PI US 5968802 19991019
 AI US 1995-482728 19950607 (8)
 RLI Utility
 DT Utility
 FS Granted
 LN.CNT 1828
 INCL INCLM: 435/233.000
 INCLM: 435/252.300; 435/254.110; 435/320.100; 536/023.200
 NCL INCLM: 435/233.000
 NCLM: 435/252.300; 435/254.110; 435/320.100; 536/023.200
 IC [6]
 ICM: C12N009-90
 ICS: C12N001-21; C12N015-63; C07H021-04
 EXF 435/233; 435/320.1; 435/252.3; 435/254.11; 536/23.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 9 OF 76 USPTAFULL
 AN 1999:124868 USPTAFULL
 TI Multivalent compounds for crosslinking receptors and uses thereof
 IN Bachovchin, William W., Melrose, MA, United States
 PA Trustees of Tufts College, Medford, MA, United States (U.S. corporation)
 PI US 5965532 19991012
 AI US 1997-837305 19970411 (8)
 RLI Continuation-in-part of Ser. No. US 1996-671756, filed on 28 Jun 1996, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3884
 INCL INCLM: 514/012.000
 INCLM: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
 NCL INCLM: 514/012.000
 NCLM: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
 IC [6]
 ICM: C07K005-00
 EXF 530/333-330; 514/12-18; 424/184.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 10 OF 76 USPTAFULL
 AN 1999:121379 USPTAFULL
 TI Screening methods for cyclokinine inhibitors
 IN Mak, Vivian, Menlo Park, CA, United States
 PA Adolor Corporation, Malvern, PA, United States (U.S. corporation)
 PI US 5962477 19991005
 AI US 1998-97441 19980615 (9)
 RLI Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-271287, filed on 6 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5138
 INCL INCLM: 514/327.000

FS Granted
LN.CNT 1255
INCL INCLM: 435/235.100
INCLM: 435/172.300; 435/069.600; 435/236.000; 424/093.200; 424/207.100
NCLM: 435/235.100
NCLM: 424/093.200; 424/207.100; 435/069.600; 435/236.000; 435/320.100;
NCLM: 435/325.000; 435/366.000
IC [6]
ICM: C12N007-00
ICS: C12N015-00; C12P021-04; A01N063-00
435/172.3; 435/235.1; 435/69.6; 435/236; 424/93.2; 424/207.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 76 USPTAFULL
AN 1999:85264 USPTAFULL
TI Vectors for gene delivery
Eftathion, Stacey, 18 Norwich Street, Cambridge, United Kingdom CB2
1NE
Ingilis, Stephen C., 2 Rhugarye Gardens, Linton, Cambridge, United Kingdom CB1 6LX
Kingdom, CBI 6LX
PI US 5928913 19990727
AI US 1996-621501 19960325 (8)
PRAI GB 1995-5892 19950323
US 1995-29P 19950608 (60)
DT Utility
FS Granted
LN.CNT 1536
INCL INCLM: 435/172.300
INCLM: 435/320.100; 435/372.300; 536/023.100; 536/023.500; 536/023.720
NCLM: 435/457.000
NCLM: 424/093.200; 435/320.100; 435/372.300; 536/023.100; 536/023.500;
NCLM: 536/023.720
IC [6]
ICM: C12N015-63
ICS: C12N005-08; C07H021-04
424/93.2; 424/93.3; 424/204.1; 424/196.11; 424/225; 424/229.1;
435/69.1; 435/91.33; 435/235.1; 435/240.2; 435/320.1; 435/172.3;
435/372.3; 514/44; 514/806; 530/350; 530/806; 536/23.1; 536/23.5;
536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 76 USPTAFULL
AN 1999:72572 USPTAFULL
TI DNA transcription unit vaccines that protect against avian influenza
viruses and methods of use thereof
Webster, Robert, Memphis, TN, United States
PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)
PI US 5916879 19990629
AI US 1996-747286 19961112 (8)
DT Utility
FS Granted
LN.CNT 1891
INCL INCLM: 514/044.000
INCLM: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;
NCLM: 424/816.000
NCLM: 514/044.000
NCLM: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;
NCLM: 536/023.720
IC [6]
ICM: A61K048-00
ICS: C12N015-87; C12N015-44
536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1
EXF

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 76 USPTAFULL
AN 1999:40232 USPTAFULL
TI Myeloid cell leukemia associated gene MCL-1
IN Craig, Ruth W., Hanover, NH, United States
PA Dartmouth College, Hanover, NH, United States (U.S. corporation)
PI US 5888812 19990330
AI US 1995-441375 19950515 (8)
RLI Division of Ser. No. US 1993-77848, filed on 16 Jun 1993, now patented, Pat. No. US 5476955 which is a continuation-in-part of Ser. No. US 1993-12307, filed on 2 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1485
INCL INCLM: 435/325.000
INCLM: 435/006.000; 435/007.230; 435/320.100; 435/235.100; 435/172.300;
530/387.700; 530/388.800; 536/023.500; 536/023.100; 935/006.000;
935/032.000; 935/034.000; 935/055.000; 935/057.000; 935/070.000;
935/071.000; 424/450.000
NCLM: 435/325.000
NCLM: 424/450.000; 435/006.000; 435/007.230; 435/235.100; 435/320.100;
NCLM: 530/387.700; 530/388.800; 536/023.100; 536/023.500
IC [6]
ICM: C07H021-00
ICS: 536/23.1; 536/23.5; 435/6; 435/7.23; 435/325; 435/320.1; 435/172.3;
435/235.1; 530/387.7; 935/24; 935/55; 935/66; 935/70; 935/71; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 76 USPTAFULL
AN 1999:24756 USPTAFULL
TI Antibodies to nuclear matrix proteins
IN Coffey, Donald S., Lutherville, MD, United States
Partin, Alan W., Baltimore, MD, United States
Getzenberg, Robert H., Branford, CT, United States
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)
PI US 5874539 19990223
AI US 1995-459023 19950602 (8)
RLI Division of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1519
INCL INCLM: 530/387.100
INCLM: 530/387.700; 530/388.100
NCLM: 530/387.100
NCLM: 530/387.700; 530/388.100
IC [6]
ICM: C07K016-18
ICS: 530/358; 530/388.15; 530/403; 530/828; 530/850; 530/854;
530/387.7; 530/387.1; 530/388.1; 435/69.3; 424/138.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 76 USPTAFULL
AN 1999:21711 USPTAFULL
TI CXG Chemokines as regulators of angiogenesis
IN Sclafner, Robert M., Ann Arbor, MI, United States
Polverini, Peter J., Ann Arbor, MI, United States
Kunkel, Steven L., Ann Arbor, MI, United States
PA The Regent of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
PI US 5871723 19990216
AI US 1995-468819 19950606 (8)
DT Utility

FS Granted
LN CNT 6055
INCL INCLM: 424/085.100
INCLS: 514/002.000; 514/008.000; 514/012.000
NCLM: 424/085.100
NCL NCLS: 514/002.000; 514/008.000; 514/012.000
IC [6]
ICM: A61K038-19
EXF 424/85.1; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 21 OF 76 USPTFLL
AN 1999-15889 USPTFLL
TI Bladder nuclear matrix proteins, polynucleotide sequences encoding them,
and their use
IN Getzenberg, Robert H., Pittsburgh, PA, United States
BAHNSON, Robert H., Pittsburgh, PA, United States
PA University of Pittsburgh, Pittsburgh, PA, United States (U.S.
corporation)
PI US 5866535 19990202
AI US 1996-742850 19961101 (8)
PRAI US 1995-6626P 19951103 (60)
DT Utility
FS Granted
LN CNT 904
INCL INCLM: 514/002.000
INCLS: 530/350.000; 530/300.000
NCLM: 514/002.000
NCL NCLS: 530/300.000; 530/350.000
IC [6]
ICM: C07K014-00
EXF 530/350; 530/300; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 22 OF 76 USPTFLL
AN 1998-157496 USPTFLL
TI CD40 coding sequences
IN Seed, Brian, Boston, MA, United States
Allen, Janet, Glasgow, Scotland
Aruffo, Alejandro, Edmonds, WA, United States
Camerini, David, Charlottesville, VA, United States
Lautner, Leander, Gladenbach, Germany, Federal Republic of
Oquendo, Carmen, Gladenbach, Germany, Federal Republic of
Simmons, David, Headington, United Kingdom
Stamenkovic, Ivan, Winchester, MA, United States
Stengelin, Siegfried, Epstein, Germany, Federal Republic of
Amiot, Martine, Nantes, France
PA The General Hospital Corporation, Charlestown, MA, United States (U.S.
corporation)
PI US 5849898 19981215
AI US 1995-485447 19950607 (8)
RLI Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a
continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990,
now abandoned which is a continuation-in-part of Ser. No. US
1990-498809, filed on 23 Mar 1990, now abandoned which is a
continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989,
now abandoned which is a continuation-in-part of Ser. No. US
1988-160416, filed on 25 Feb 1988, now abandoned
DT Utility
FS Granted
LN CNT 3541
INCL INCLM: 536/023.500
INCLS: 435/069.100; 435/257.300; 435/320.100
NCL NCLM: 536/023.500

IC NCLS: 435/069.100; 435/257.300; 435/320.100
[6]
EXF 536/23.5; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 23 OF 76 USPTFLL
AN 1998-157126 USPTFLL
TI Nuclear matrix proteins
IN Coffey, Donald S., Lutherville, MD, United States
Partin, Alan W., Baltimore, MD, United States
Getzenberg, Robert H., Branford, MD, United States
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United
States (U.S. corporation)
PI US 5849509 19981215
AI US 1995-488036 19950607 (8)
RLI Division of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned
DT Utility
FS Granted
LN CNT 1514
INCL INCLM: 435/007.230
INCLS: 435/007.100; 436/064.000; 436/813.000
NCLM: 435/007.230
NCL NCLS: 435/007.100; 436/064.000; 436/813.000
IC [6]
ICM: G01N033-574
EXF 435/7.1; 435/7.23; 530/387.1; 530/388.1; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 24 OF 76 USPTFLL
AN 1998-154116 USPTFLL
TI Fungal Protease
IN Buxton, Frank, Holderstudeilweg 32, 4132 Muttenz, Switzerland
Hinzen, Albert, Am Planetarium 32, 07743 Jena, Germany, Federal Republic
of
PI US 5846802 19981208 (8)
AI US 1994-225488 19940408 (8)
RLI Continuation-in-part of Ser. No. US 1993-47214, filed on 13 Apr 1993,
now abandoned
PRAI GB 1992-810281 19920415
GB 1993-5097 19930312
DT Utility
FS Granted
LN CNT 2659
INCL INCLM: 435/225.000
INCLS: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;
435/014.000; 435/028.000; 435/068.000; 536/023.200
NCLM: 435/225.000
NCL NCLS: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;
536/023.200
IC [6]
ICM: C12N015-57
EXF 435/225; 435/69.1; 435/172.3; 435/252.3; 435/254.3; 435/320.1;
536/252.3; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 25 OF 76 USPTFLL
AN 1998-150739 USPTFLL
TI Alphavirus vector constructs
IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 Belli, Barbara A., San Diego, CA, United States
 Chicon Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 5843723 19981201
 AI US 1996-739167 19961030 (8)
 RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 FS Granted
 LN CNT 10318
 INCL INCLM: 435/069.300
 NCL INCLS: 435/320.100; 435/325.000; 435/235.100
 NCLM: 435/069.300
 NCLS: 435/235.100; 435/320.100; 435/325.000
 IC [6]
 ICM: C12P021-02
 ICS: C12N015-63; C12N005-10
 EXF 435/320.1; 435/325; 435/69.3; 435/235.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 26 OF 76 USPTAFULL
 AN 1998:144236 USPTAFULL
 TI NF-AT polypeptides and polynucleotides
 IN Crabtree, Gerald R., Woodside, CA, United States
 Northrop, Jeffrey P., Campbell, CA, United States
 Board of Trustees of Ireland Stanford Jr. University, Stanford, CA, United States
 PI US 5837840 19981117
 AI US 1993-124981 19930920 (8)
 DT Utility
 FS Granted
 LN CNT 2291
 INCL INCLM: 536/023.400
 NCL INCLS: 536/023.100; 536/024.300
 NCLM: 536/023.400
 NCLS: 536/023.100; 536/024.300
 IC [6]
 ICM: C07H021-04
 ICS: 530/350; 435/69.1; 435/320.1; 435/240.2; 536/23.1; 536/23.5
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 27 OF 76 USPTAFULL
 AN 1998:134881 USPTAFULL
 TI Cloning vector, polylinker and methods
 IN Seed, Brian, Boston, MA, United States
 Aruffo, Alejandro, Edmonds, WA, United States
 The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)
 PI US 5830731 19981103
 AI US 1997-861205 19970521 (8)
 RLI Continuation of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned
 DT Utility

FS Granted
 LN CNT 3587
 INCL INCLM: 435/172.300
 NCL INCLS: 435/252.300; 435/320.100; 536/024.200
 NCLM: 435/091.410
 NCLS: 435/252.300; 435/320.100; 536/024.200
 IC [6]
 ICM: C12N015-66
 EXF 435/252.7; 435/320.1; 435/172.3; 536/24.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 28 OF 76 USPTAFULL
 AN 1998:134627 USPTAFULL
 TI Yeast-based delivery vehicles
 IN Duke, Richard C., Denver, CO, United States
 Franzusoff, Alex, Boulder, CO, United States
 Bellgrau, Donald, Denver, CO, United States
 University Technology Corporation, Boulder, CO, United States (U.S. corporation)
 PI US 5830463 19981103
 AI US 1994-340185 19941115 (8)
 RLI Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now patented, Pat. No. US 5413914
 DT Utility
 FS Granted
 LN CNT 1929
 INCL INCLM: 424/093.510
 NCL INCLS: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300; 435/069.100
 NCLM: 424/093.510
 NCLS: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000
 IC [6]
 ICM: C12N015-00
 ICS: C12N015-09; A61K048-00
 EXF 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31; 514/44; 935/62; 935/52; 935/55; 935/56; 935/57; 935/34; 935/32; 424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 29 OF 76 USPTAFULL
 AN 1998:128084 USPTAFULL
 TI Method for detecting prostate cancer using a reagent which binds prostate cancer-1 protein
 IN Coffey, Donald S., Lutherville, MD, United States
 Partin, Alan W., Baltimore, MD, United States
 Getzenberg, Robert H., Pittsburgh, PA, United States
 The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)
 PI US 5824490 19981020
 AI US 1995-455558 19950531 (8)
 RLI Continuation-in-part of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned
 DT Utility
 FS Granted
 LN CNT 1572
 INCL INCLM: 435/007.230
 NCL INCLS: 435/007.100; 436/064.000; 436/813.000
 NCLM: 435/007.230
 NCLS: 435/007.100; 436/064.000; 436/813.000
 IC [6]
 ICM: G01N033-574
 ICS: G01N033-53
 EXF 435/7.1; 435/7.23; 530/387.1; 530/388.1; 436/64; 436/813
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 76 USPTAFULL
 AN 1998:119004 USPTAFULL
 TI Eukaryotic layered vector initiation systems
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Santa Fe, CA, United States 92024
 States 92067
 Polio, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024
 Driver, David A., 5142 Baltimore St., San Diego, CA, United States 92117
 PI US 5814482 19980929
 AI US 1996-739158 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 10431
 INCL INCLM: 435/069.300
 INCL: 435/320.100; 536/023.100; 536/024.100
 NCL NCIM: 435/069.300
 NCL: 435/320.100; 536/023.100; 536/024.100
 IC [6]
 ICM: C12P021-00
 ICS: C12N015-86; C07H021-04
 EXF 435/69.3; 435/320.1; 536/23.1; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 31 OF 76 USPTAFULL
 AN 1998:108036 USPTAFULL
 TI Recombinant canine herpesviruses
 IN Haanes, Elizabeth J., Berthoud, CO, United States
 Frank, Rexann S., Wellington, CO, United States
 Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
 PI US 5804197 19980908
 AI US 1996-680726 19960712 (8)
 RLI Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996
 DT Utility
 FS Granted
 LN.CNT 5536
 INCL INCLM: 424/229.100
 INCL: 424/199.100; 435/235.100; 435/320.100
 NCL NCIM: 424/229.100
 NCL: 424/199.100; 435/235.100; 435/320.100
 IC [6]
 ICM: A61K039-245
 ICS: A61K039-00; C12N007-01; C12N015-00
 EXF 424/229.1; 424/199.1; 435/235.1; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 32 OF 76 USPTAFULL
 AN 1998:91872 USPTAFULL
 TI Alphavirus structural protein expression cassettes
 IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polio, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M., W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5789245 19980804
 AI US 1996-741881 19961030 (8)
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 10270
 INCL INCLM: 435/320.100
 INCL: 435/691.000; 435/325.000; 536/023.720
 NCL NCIM: 435/320.100
 NCL: 435/069.100; 435/325.000; 536/023.720
 IC [6]
 ICM: C12N015-63
 ICS: C12N015-40; C12N005-10; C12P021-02
 EXF 435/320.1; 435/69.1; 435/325; 536/23.72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 33 OF 76 USPTAFULL
 AN 1998:79186 USPTAFULL
 TI Use of quinoline-3-carboxamide compounds for inhibiting the production of tumor necrosis factor (TNF) and/or for the treatment of septic shock
 IN Kroemer, Guido Peter, Madrid, Spain
 Gonzalez, Joseangel, Madrid, Spain
 Alonso, Carlos Martinez, Madrid, Spain
 Kalland, Terje, Loddekoping, Sweden
 Pharmacia AB, Stockholm, Sweden (non-U.S. corporation)
 PI US 5776947 19980707
 AI WO 9503051 19950202
 WO 1996-586857 19940610
 WO 1994-SE565 19960520 PCT 371 date
 19960520 PCT 102(e) date
 PRAT SE 1993-2490 19930726
 DT Utility
 FS Granted
 LN.CNT 535
 INCL INCLM: 514/312.000
 INCL: 514/313.000
 NCL NCIM: 514/312.000
 NCL: 514/313.000
 IC [6]
 ICM: A61K031-47
 ICS: 514/312; 514/313
 EXF 514/312; 514/313
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 34 OF 76 USPTAFULL
 AN 1998:69157 USPTAFULL
 TI Afamin: a human serum albumin-like protein
 IN Lichenstein, Henri Stephen, Ventura, CA, United States
 Lyons, David Edwin, Thousand Oaks, CA, United States
 Wurfe, Mark Matsuo, New York, NY, United States
 Wright, Samuel Donald, Larchmont, NY, United States
 Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
 The Rockefeller University, New York, NY, United States (U.S. corporation)
 PI US 5767243 19980616
 AI US 1997-816920 19970313 (8)
 RLI Division of Ser. No. US 1994-222619, filed on 31 Mar 1994, now patented, Pat. No. US 5652352

DT Utility
FS Granted
LN.CNT 1863
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [6]
ICM: C07K013-00
530/350; 530/387.1
EXF 530/350; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 76 USPTAFULL
AN 1998:68822 USPTAFULL
TI Cysteine-pegylated proteins
IN Braxton, Scott M., San Mateo, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5766897
AI US 1995-427100
RLI 19980616
19950421 (8)
Continuation-in-part of Ser. No. US 1993-144758, filed on 29 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-924294, filed on 3 Aug 1992, now patented, Pat. No. US 5457090 which is a continuation of Ser. No. US 1990-542484, filed on 21 Jun 1990, now patented, Pat. No. US 5187089, issued on 16 Feb 1993

DT Utility
FS Granted
LN.CNT 2765
INCL INCLM: 435/172.100
INCLS: 435/188.000; 435/212.000; 435/219.000
NCL NCLM: 435/463.000
NCLS: 435/188.000; 435/212.000; 435/219.000
IC [6]
ICM: C12N015-00
ICS: C12N009-96; C12N009-48; C12N009-50
EXF 514/12; 530/350; 435/69.2; 435/188; 435/172.1; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 76 USPTAFULL
AN 1998:65353 USPTAFULL
TI HIV-specific synthetic antigens and their use
IN Conley, Anthony J., Exton, PA, United States
PA Arnold, Beth A., Quakertown, PA, United States
Boots, Lynn J., Lansdale, PA, United States
Keller, Paul M., Lansdale, PA, United States
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5763574
AI 19980609
US 1996-625691
RLI 19960404 (8)
Continuation of Ser. No. US 1994-323338, filed on 14 Oct 1994, now abandoned

DT Utility
FS Granted
LN.CNT 1123
INCL INCLM: 530/326.000
INCLS: 530/350.000; 530/395.000; 424/188.100; 424/184.100; 424/208.100;
NCL NCLM: 530/326.000
NCLS: 424/184.100; 424/188.100; 424/204.100; 424/208.100; 530/350.000;
530/395.000
IC [6]
ICM: A61K038-00
ICS: A61K039-21; C07K005-00; C07K007-00
EXF 424/188.1; 424/184.1; 424/204.1; 530/350; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 76 USPTAFULL

AN 1998:57762 USPTAFULL
TI Aspergillus niger vacuolar aspartyl protease
IN Buxton, Frank, Murtens, Switzerland
Jara, Gabor, Oberwil, Switzerland
Visser, Jacod, Wageningen, Netherlands
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5756338
AI US 1996-731045
RLI 19980526
US 1996-731045
Division of Ser. No. US 1994-32831M, filed on 24 Oct 1994, now patented, Pat. No. US 5674728, issued on 7 Oct 1997

PRAI GB 1993-810764 19931103

DT Utility
FS Granted
LN.CNT 1957
INCL INCLM: 435/219.000
INCLS: 435/254.300; 536/023.200
NCL NCLM: 435/219.000
NCLS: 435/254.300; 536/023.200
IC [6]
ICM: C12N009-62
ICS: C12N015-57; C12N015-63; C12N015-80
EXF 435/219; 435/254.3; 435/2; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 76 USPTAFULL
AN 1998:54490 USPTAFULL
TI Recombinant canine herpesviruses
IN Hannes, Elizabeth J., Boulder, CO, United States
Frank, Rexann S., Wellington, CO, United States
Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
PA US 5753235
AI 19980519
US 1996-602010
RLI 19960215 (8)
Utility
FS Granted
LN.CNT 3143
INCL INCLM: 424/229.100
INCLS: 424/147.100; 435/235.100; 530/388.300; 530/395.000
NCL NCLM: 424/229.100
NCLS: 424/147.100; 435/235.100; 530/388.300; 530/395.000
IC [6]
ICM: A61K039-245
ICS: C12N007-01; C07K001-00; C12P021-02
EXF 424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 76 USPTAFULL
AN 1998:36744 USPTAFULL
TI Method for treating vascular leak syndrome
IN Siegall, Clay, Seattle, WA, United States
Chace, Dana, Seattle, WA, United States
Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 5736536
AI 19980407
US 1997-795751
RLI 19970206 (8)
Division of Ser. No. US 1994-253351, filed on 19 Aug 1994

DT Utility
FS Granted
LN.CNT 696
INCL INCLM: 514/165.000
INCLS: 514/226.500; 514/420.000; 514/566.000; 514/561.000; 514/570.000
NCL NCLM: 514/165.000
NCLS: 514/226.500; 514/420.000; 514/566.000; 514/569.000; 514/570.000
IC [6]
ICM: A61K031-60

ICS: A61K061-54; A61K031-54
 EXF 514/226.5; 514/420; 514/569; 514/570; 514/165
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 76. USPATFULL
 AN 1998:30684 USPATFULL
 TI Method and compositions for solubilization and stabilization of
 IN polypeptides, especially proteins
 Hora, Maninder Singh, Rodeo, CA, United States
 Rubinfield, Joseph, Danville, CA, United States
 Stern, Warren, Gainesville, FL, United States
 Wong, Gregory J., San Leandro, CA, United States
 Chilton Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 5730969 19980324
 AI US 1995-474178 19950607 (8)
 RLI Division of Ser. No. US 1989-373928, filed on 29 Jun 1989 which is a
 continuation-in-part of Ser. No. US 1988-253720, filed on 5 Oct 1988,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 1753
 INCL INCLM: 424/085.100
 INCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;
 514/003.000; 514/012.000; 514/021.000
 NCL NCIM: 424/085.100
 NCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;
 514/003.000; 514/012.000; 514/021.000

IC [6]
 ICM: A61K038-17
 ICS: A61K038-19; A61K038-20; A61K038-49
 EXF 435/188; 424/85.1; 424/85.2; 424/85.4; 424/85.5; 424/85.6; 424/85.7;
 424/94.3; 530/303; 530/351; 530/399; 514/2; 514/3; 514/12; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 41 OF 76. USPATFULL
 AN 1998:28183 USPATFULL
 TI Use of cyclohextrins for protein renaturation
 IN Sharma, Ajit, Mount Pleasant, MI, United States
 Karupiah, Nadarajah, Mount Pleasant, MI, United States
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
 corporation)
 PI US 5728804 19980317
 AI US 1995-460234 19950602 (8)
 DT Utility
 FS Granted
 LN.CNT 672
 INCL INCLM: 530/350.000
 INCLS: 530/351.000; 530/399.000; 530/414.000; 530/417.000; 514/021.000;
 435/069.100; 435/069.400; 435/069.500; 435/158.000
 NCL NCIM: 530/350.000
 NCLS: 435/069.100; 435/069.400; 435/069.500; 435/188.000; 530/351.000;
 530/399.000; 530/414.000; 530/417.000

IC [6]
 ICM: C07K001-00
 ICS: C12P021-06
 EXF 530/350; 530/351; 530/399; 530/414; 530/417; 514/21; 435/69.1; 435/69.4;
 435/69.5; 435/188
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 42 OF 76. USPATFULL
 AN 1998:27762 USPATFULL
 TI Methods and compositions incorporating IP-10
 IN Sarits, Andreas H., Houston, TX, United States
 Broxmeyer, Hal E., Indianapolis, IN, United States

PA Ravetch, Jeff V., New York, NY, United States
 Board of Regents, The University of Texas System, Austin, TX, United
 States (U.S. corporation)
 Indiana University Foundation, Bloomington, IN, United States (U.S.
 corporation)
 Sloan-Kettering Institute for Cancer Research, New York, NY, United
 States (U.S. corporation)
 PI US 5728377 19980317
 AI US 1993-94851 19930720 (8)
 DT Utility
 FS Granted
 LN.CNT 1630
 INCL INCLM: 424/085.100
 INCLS: 435/069.500; 530/351.000
 NCL NCIM: 424/085.100
 NCLS: 435/069.500; 530/351.000

IC [6]
 ICM: A61K045-05
 EXF 424/85.1; 435/69.5; 530/351; 935/13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 76. USPATFULL
 AN 1998:11702 USPATFULL
 TI Hybrid immunoglobulins
 IN Capon, Daniel J., San Mateo, CA, United States
 Lasky, Laurence A., Sausalito, CA, United States
 PA Genentech Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5714147 19980203
 AI US 1995-451848 19950526 (8)
 RLI Continuation of Ser. No. US 1994-185670, filed on 21 Jan 1994, now
 patented, Pat. No. US 5514582 which is a continuation of Ser. No. US
 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US 5428130
 which is a continuation of Ser. No. US 1991-808122, filed on 19 Dec
 1991, now patented, Pat. No. US 5225938 which is a division of Ser. No.
 US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964
 which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23
 Feb 1989, now patented, Pat. No. US 5098533

DT Utility
 FS Granted
 LN.CNT 2709
 INCL INCLM: 424/178.100
 INCLS: 435/697.000; 530/387.100; 536/023.400
 NCL NCIM: 424/178.100
 NCLS: 435/069.700; 530/387.100; 536/023.700

IC [6]
 ICM: A61K039-395
 EXF 435/69.7; 514/2; 530/35; 530/387.1; 536/23.4; 424/178.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 76. USPATFULL
 AN 97:114931 USPATFULL
 TI Modified anti-TCM-1 antibodies and their use in the treatment of
 IN inflammation
 Faanes, Ronald Bertrand, Pound Ridge, NY, United States
 McGoff, Paul Edward, Watertown, CT, United States
 Shirley, Bret Allen, New Milford, CT, United States
 Scher, David Stuart, Danbury, CT, United States
 PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United
 States (U.S. corporation)
 PI US 5695760 19971209
 AI US 1995-427355 19950424 (8)
 DT Utility
 FS Granted

LN.CNT 3085
INCL INCLM: 424/178.100
INCL: 424/181.100; 530/391.100; 530/388.850
NCLM: 424/178.100
NCL: 424/181.100; 530/388.850; 530/391.100
IC [6]
ICM: A61K039-395
ICS: C07K016-28
EXF 530/391.1; 530/388.85; 424/181.1; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 76 USPATFULL
AN 97:112357 USPATFULL
TI Anti-cancer immunotherapeutics
IN Chada, Sunil, Vista, CA, United States
Bodner, Mordcheai, San Diego, CA, United States
Jolly, Douglas J., La Jolla, CA, United States
Barber, Jack R., San Diego, CA, United States
DeJesus, Cary E., San Diego, CA, United States
Chilton Viagene, Inc., United States (U.S. corporation)
PI US 5693522
PI 19971202
PI 19950111 (8)
R1 Continuation of Ser. No. 1993-104424, filed on 9 Aug 1993, now abandoned which is a continuation of Ser. No. US 1991-800328, filed on 29 Nov 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1669
INCL INCLM: 435/002.402
INCL: 435/172.300; 435/320.100; 536/023.100
NCLM: 435/325.000
NCL: 435/320.100; 435/350.000; 435/353.000; 435/357.000; 435/364.000; 435/366.000; 536/023.100
IC [6]
ICM: C12N015-00
ICS: C12N005-00; C07H021-02
EXF 435/320.1; 435/172.3; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 76 USPATFULL
AN 97:107067 USPATFULL
TI Method for treating vascular leak syndrome
IN Siegall, Clay, Seattle, WA, United States
Chace, Dana, Seattle, WA, United States
Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)
PI US 5688781
PI 19971118
PI 1994293351
PI 19940819 (8)
AI US 1994-293351
DT Utility
FS Granted
LN.CNT 814
INCL INCLM: 514/179.000
NCLM: 514/179.000
NCL [6]
ICM: A61K031-56
EXF 514/179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 76 USPATFULL
AN 97:99018 USPATFULL
TI Lymphokine gene therapy of cancer
IN Sobol, Robert E., La Jolla, CA, United States
Gage, Fred H., La Jolla, CA, United States
Royston, Ivor, La Jolla, CA, United States

PA Friedman, Theodore, La Jolla, CA, United States
Fakhrai, Habib, Oceanside, CA, United States
Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S. corporation)
PI US 5685623
PI 19971028
PI 19941209 (8)
R1 Continuation of Ser. No. US 1992-863641, filed on 3 Apr 1992, now abandoned Continuation-in-part of Ser. No. US 1991-781356, filed on 25 Oct 1991, now abandoned Continuation-in-part of Ser. No. US 1991-720872, filed on 25 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2156
INCL INCLM: 424/093.210
INCL: 435/240.200; 435/320.100; 435/172.300; 435/069.500; 424/184.100; 424/277.100
NCLM: 424/093.210
NCL: 424/184.100; 424/277.100; 435/069.500; 435/320.100
IC [6]
ICM: A61K048-00
ICS: A61K039-00; C12N005-00
EXF 435/69.1; 435/69.5; 435/69.51; 435/69.52; 435/69.3; 435/320.1; 435/240.2; 435/172.3; 435/7.2; 530/350; 530/351; 514/44; 514/2; 514/12; 424/85.1; 424/85.2; 424/85.2; 424/93.21; 424/93; 935/52; 935/55; 935/57; 935/32; 935/66; 935/70; 935/71; 935/33; 935/34; 935/65
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 76 USPATFULL
AN 97:91390 USPATFULL
TI Aspergillus niger vacuolar aspartyl protease
IN Buxton, Frank, Nutcr, Switzerland
Jara, Gabor, Oberwil, Switzerland
Vasser, Jacob, Wageningen, Netherlands
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5674728
PI 19971007
PI 19941024 (8)
R1 EP 1993-810764
R1 19931103
DT Utility
FS Granted
LN.CNT 2018
INCL INCLM: 435/225.000
INCL: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/172.300; 435/320.100; 536/023.200
NCLM: 435/225.000
NCL: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/320.100; 435/477.000; 435/488.000; 536/023.200
IC [6]
ICM: C12N015-58
ICS: C12N015-80; C12N009-62
EXF 435/219; 435/223; 435/225; 435/252.3; 435/254.11; 435/254.3; 435/172.3; 435/320.1; 435/69.1; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 49 OF 76 USPATFULL
AN 97:66235 USPATFULL
TI Aflatin: a human serum albumin-like gene
IN Lichenstein, Henri Stephen, Ventura, CA, United States
Lyons, David Edwin, Thousand Oaks, CA, United States
Wurfel, Mark Matsuo, New York, NY, United States
Wright, Samuel Donald, Larchmont, NY, United States
PA Angen Inc., Thousand Oaks, CA, United States (U.S. corporation)
The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5652352
PI 19970729

AI US 1994-2222619 19940331 (8)
 DT Utility
 FS Granted
 LN CNT 1870
 INCL INCLM: 536/023.500
 NCL INCLS: 536/023.100; 435/069.100
 NCLM: 536/023.500
 NCLM: 435/069.100; 536/023.100
 IC [6]
 ICM: C07H021-02
 ICS: C07H021-04; C12P021-00
 EXF 435/6; 435/320.1; 435/69.1; 536/23.1; 536/23.5; 536/24.3; 536/23.2;
 536/24.5; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 50 OF 76 USPATFULL
 AN 97:29343 USPATFULL
 TI Carcinoma associated antigen (SKI) monoclonal antibodies against SKI,
 methods of producing these antibodies and use thereof
 IN Classy, Mark C., San Diego, CA, United States
 Chang, Helena R., Providence, RI, United States
 Kodai, Keiji, Chiba, Japan
 Sci-Clone, Inc., San Diego, CA, United States (U.S. corporation)
 PA The Regents of the University of California, Oakland, CA, United States
 PI US 5637493 19970610
 AI US 1994-201243 19940224 (8)
 RLI Continuation-in-part of Ser. No. US 1992-827717, filed on 29 Jan 1992,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 1245
 INCL INCLM: 435/327.000
 INCLS: 530/388.800; 530/388.850; 530/387.200; 530/388.150; 935/100.000;
 NCLM: 435/327.000
 NCLM: 435/344.100
 NCLM: 435/344.100
 NCLM: 435/344.100; 530/387.200; 530/388.150; 530/388.800; 530/388.850
 IC [6]
 ICM: C07K016-30
 ICS: C07K016-42; C12N005-12
 EXF 435/240.27; 530/387.2; 530/388.15; 530/388.8; 530/388.85; 935/100
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 51 OF 76 USPATFULL
 AN 97:29374 USPATFULL
 TI Oncostatin M and novel compositions having anti-neoplastic activity
 IN Zarling, Joyce M., Seattle, WA, United States
 Marquardt, Hans, Mercer Island, WA, United States
 Hanson, Marcia B., Seattle, WA, United States
 Malik, Najma, Seattle, WA, United States
 Linsley, Peter S., Seattle, WA, United States
 Rose, Timothy M., Seattle, WA, United States
 PA Purcino, Anthony F., Seattle, WA, United States
 Oncogen Limited Partnership, Seattle, WA, United States (U.S.
 corporation)
 PI US 5618715 19970408
 AI US 1993-75199 19930610 (8)
 RLI Continuation of Ser. No. US 1991-689723, filed on 22 Apr 1991, now
 abandoned which is a continuation of Ser. No. US 1988-144574, filed on
 15 Jan 1988, now abandoned which is a continuation-in-part of Ser. No.
 US 1987-15139, filed on 30 Oct 1987, now abandoned which is a
 continuation-in-part of Ser. No. US 1987-46846, filed on 4 May 1987, now
 patented, Pat. No. US 5120535, issued on 9 Jun 1992 which is a

DT continuation-in-part of Ser. No. US 1986-935283, filed on 26 Nov 1986,
 now abandoned which is a continuation-in-part of Ser. No. US
 1985-811235, filed on 20 Dec 1985, now abandoned
 FS Utility
 LN CNT 2185
 INCL INCLM: 435/325.000
 INCLS: 435/069.100; 435/069.400; 435/320.100; 435/348.000; 435/360.000;
 435/365.100; 435/364.000; 536/023.100; 536/023.510; 530/300.000;
 NCLM: 435/325.000
 NCLM: 435/365.100; 435/364.000; 435/069.100; 435/069.400; 435/320.100; 435/348.000; 435/360.000;
 NCLM: 435/364.000; 435/365.100; 536/300.000; 530/351.000; 536/023.100;
 536/023.510
 IC [6]
 ICM: C12N005-00
 ICS: C12N015-00; C12P021-06; C07H017-00
 EXF 530/300; 530/351; 536/23.1; 536/23.4; 435/320.1; 435/69.1; 435/69.4;
 435/69.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 52 OF 76 USPATFULL
 AN 97:29349 USPATFULL
 TI Method of using an ER-located endoprotease
 IN Chaudhuri, Bhabatosh, Munchenstern, Switzerland
 Stephan, Christine, Kingersheim, France
 Seebach, Peter, Inzlingen, Germany, Federal Republic of
 Riezman, Howard, Biel-Benken, Switzerland
 PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
 PI US 5618690 19970408
 AI US 1995-462397 19950605 (8)
 RLI Division of Ser. No. US 1994-328961, filed on 24 Oct 1994, now patented,
 Pat. No. US 5501975 which is a continuation of Ser. No. US 1992-989260,
 filed on 11 Dec 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1412
 INCL INCLM: 435/068.100
 INCLS: 435/069.100; 435/069.700; 435/219.000; 435/223.000
 NCLM: 435/068.100
 NCLM: 435/069.100; 435/069.700; 435/219.000; 435/223.000
 IC [6]
 ICM: C12P021-06
 ICS: C12N009-50
 EXF 435/68.1; 435/69.1; 435/69.7; 435/219; 435/223
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 53 OF 76 USPATFULL
 AN 97:3950 USPATFULL
 TI Chimera protein comprising an RTX-family cytotoxin and
 interferon-2 or interferon
 IN Potter, Andrew, Saskatoon, Canada
 Campos, Manuel, Lincoln, NE, United States
 PA Hughes, Huw P. A., Saskatoon, Canada
 University of Saskatchewan, Saskatoon, Canada
 Ciba-Geigy Canada Ltd., Mississauga, Canada (non-U.S. corporation)
 PI US 5594107 19970114
 AI US 1993-170126 19931220 (8)
 RLI Continuation-in-part of Ser. No. US 1991-777715, filed on 16 Oct 1991,
 now patented, Pat. No. US 5273889 which is a continuation-in-part of
 Ser. No. US 1990-571301, filed on 22 Aug 1990, now patented, Pat. No. US
 5238823
 DT Utility

FS Granted
LN.CNT 1851
INCL INCLM: 530/350.000 435/069.700; 530/351.000; 530/825.000; 424/192.100;
INCLM: 424/195.110; 424/197.110; 424/085.100
NCLM: 530/350.000
NCLM: 424/085.100; 424/192.100; 424/195.110; 424/197.110; 435/069.500;
NCLM: 433/069.700; 530/351.000; 530/825.000
IC [6]
ICM: C12N015-19
ICS: A61K039-102
EXF 530/351: 530/350; 530/324; 530/825; 435/69.5; 435/69.7; 424/192.1;
424/195.11; 424/197.11; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 54 OF 76 USPATFULL
AN 96:109073 USPATFULL
TI Soluble interferon-gamma receptor fragment
IN Novick, Daniela, Rehovot, Israel
Rubinstein, Menachem, Givat Shmuel, Israel
PA Yeda Research and Development, Co., Ltd., Rehovot, Israel (non-U.S. corporation)
PI US 5578707 19961126
AI US 1993-16992 19930212 (8)
RLI Division of Ser. No. US 1990-578826, filed on 7 Sep 1990, now patented, Pat. No. US 5221789
PRAI ID 1989-91562 19890907
DT Utility
FS Granted
LN.CNT 608
INCL INCLM: 530/395.000
INCLM: 530/350.000; 530/403.000; 435/069.100; 435/069.700; 424/525.000
NCLM: 530/395.000
NCLM: 424/525.000; 435/069.100; 435/069.700; 530/350.000; 530/403.000
IC [6]
ICM: C07K014-715
ICS: A61K038-17
EXF 514/8: 530/395; 530/350; 530/403; 435/69.1; 435/69.7; 424/525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 55 OF 76 USPATFULL
AN 96:38806 USPATFULL
TI Recombinant DNA encoding hybrid immunoglobulins
IN Capon, Daniel J., San Mateo, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
PI US 5514582 19960507
AI US 1994-185670 19940121 (8)
RLI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US 5428130 which is a continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538 which is a division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833
DT Utility
FS Granted
LN.CNT 2644
INCL INCLM: 435/252.300
INCLM: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530
NCLM: 435/252.300
NCLM: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530
IC [6]
ICM: C12N015-62

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 56 OF 76 USPATFULL
AN 96:29456 USPATFULL
TI Rapid immunoselection cloning method
IN Seed, Brian, Boston, MA, United States
Aruffo, Alejandro, Edmonds, WA, United States
PA The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)
PI US 5506126 19960409
AI US 1993-139273 19931018 (8)
RLI Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned
DT Utility
FS Granted
LN.CNT 3560
INCL INCLM: 435/172.300
INCLM: 435/320.100; 536/024.200
NCLM: 435/006.000
NCLM: 435/320.100; 536/024.200
IC [6]
ICM: C12N015-10
EXF 435/172.3; 435/320.1; 536/24.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 57 OF 76 USPATFULL
AN 96:24862 USPATFULL
TI DNA molecules encoding an ER-located endoprotease
IN Chaudhuri, Bhabatosh, Munchenstein, Switzerland
Stephan, Christine, Kingersheim, France
Seebach, Peter, Inzlingen, Germany, Federal Republic of
Rietman, Howard, Biel-Benken, Switzerland
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5501975 19960326
AI US 1994-328961 19941024 (8)
RLI Continuation of Ser. No. US 1992-989260, filed on 11 Dec 1992, now abandoned
PRAI EP 1991-810984 19911216
DT Utility
FS Granted
LN.CNT 1398
INCL INCLM: 435/252.300
INCLM: 536/023.400; 536/023.200; 435/223.000; 435/069.700; 435/069.800; 435/069.900; 435/320.100; 935/048.000; 935/014.000
NCLM: 435/252.300
NCLM: 435/069.700; 435/069.800; 435/069.900; 435/223.000; 435/320.100; 536/023.200; 536/023.400
IC [6]
ICM: C12N015-62
ICS: C12N015-63; C12N015-57
EXF 435/223; 435/219; 435/69.7; 435/69.8; 435/69.9; 435/252.3; 435/320.1; 935/10; 935/14; 935/47; 935/48; 935/49; 536/23.2; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 58 OF 76 USPATFULL
AN 95:110429 USPATFULL
TI Use of the cytokine IP-10 as an anti-tumor agent
IN Leder, Philip, Chestnut Hill, MA, United States
Luster, Andrew, Wellesley, MA, United States

PA President and Fellows of Harvard College, Cambridge, MA, United States
(U.S. corporation)
PI US 5474981 19951212
AI US 1994-217016 19940323 (8)
RI Continuation of Ser. No. US 1992-935587, filed on 26 Aug 1992, now
abandoned
DT Utility
FS Granted
INCL INCLM: 514/012.000
INCLM: 514/002.000; 514/908.000; 530/350.000; 530/351.000
NCLM: 514/012.000
NCLM: 514/002.000; 514/908.000; 530/350.000; 530/351.000
ICM: A61K038-16
ICS: A61K038-17; A61K038-18; C07K014-475
EXF 514/2; 514/12; 514/908; 530/324; 530/350; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 59 OF 76. USPATFULL
AN 95:105945 USPATFULL
TI Antibodies which specifically bind mcl-1 polypeptide
IN Craig, Ruth W., Hanover, NH, United States
PA Dartmouth College, Hanover, NH, United States (U.S. corporation)
PI US 5470955 19951128
AI US 1993-77848 19930616 (8)
RI Continuation-in-part of Ser. No. US 1993-12307, filed on 2 Feb 1993, now
abandoned
DT Utility
FS Granted
INCL INCLM: 530/387.700
INCLM: 530/388.800; 530/388.850; 530/389.100; 530/389.700
NCLM: 530/387.700
NCLM: 530/388.800; 530/388.850; 530/389.100; 530/389.700
ICM: C07K016-00
ICS: C07K016-30
EXF 530/388.8; 530/389.7; 435/240.27; 435/172.2; 435/70.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 60 OF 76. USPATFULL
AN 95:88382 USPATFULL
TI Expression vector encoding hybrid immunoglobulins
IN Capon, Daniel J., San Mateo, CA, United States
PA Genentech Inc., San Francisco, CA, United States (U.S. corporation)
PI US 5455165 19951003
AI US 1994-183669 19940121 (8)
RI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992 which is a
continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now
patented, Pat. No. US 5225538 which is a division of Ser. No. US
1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964
which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23
Feb 1989, now patented, Pat. No. US 5098833
DT Utility
FS Granted
INCL INCLM: 435/064.700
INCLM: 435/250.300; 435/320.100; 536/023.400
NCLM: 435/064.700
NCLM: 435/250.300; 435/320.100; 536/023.400
ICM: G01N033-74
ICS: G01N033-68; G01N033-60; C07K013-00
EXF 435/7.23; 435/7.21; 435/960; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 61 OF 76. USPATFULL
AN 95:84455 USPATFULL
TI Antagonists of human gamma interferon
IN Seelig, Gail F., Watchung, NJ, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5451658 19950919
AI WO 9206115.19920416 19930319 (8)
RI WO 1991-058771 19910925
WO 1991-058771 19930319 PCT 371 date
PCT 102(e) date
RI Continuation-in-part of Ser. No. US 1990-589106, filed on 27 Sep 1990,
now abandoned
DT Utility
FS Granted
INCL INCLM: 530/300.000
INCLM: 530/324.000; 530/326.000; 530/351.000
NCLM: 530/300.000
NCLM: 530/324.000; 530/326.000; 530/351.000
ICM: C07K007-00
ICS: C07K014-00
EXF 424/85.8; 435/70.4; 435/172.2; 435/240.27; 435/69.6; 435/69.1; 514/2;
530/351; 530/387.1; 530/387.2; 530/388.1; 530/388.23; 530/300; 530/324;
530/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 62 OF 76. USPATFULL
AN 95:84304 USPATFULL
TI Oncostatin M and novel compositions having anti-neoplastic activity
IN Shoyab, Mohammed, Seattle, WA, United States
PA Zarling, Joyce M., Seattle, WA, United States
Margardt, Hans, Mercer Island, WA, United States
Hanson, Marcia B., Seattle, WA, United States
Linsley, Peter S., Seattle, WA, United States
Oncogen Limited Partnership, Seattle, WA, United States (U.S.
corporation)
PI US 5451506 19950919
AI US 1993-78707 19930616 (8)
RI Continuation of Ser. No. US 1989-397676, filed on 2 Oct 1989, now
abandoned And a continuation-in-part of Ser. No. US 1987-46846, filed on
4 May 1987, now patented, Pat. No. US 5120535 which is a
continuation-in-part of Ser. No. US 1986-935283, filed on 26 Nov 1986,
now abandoned which is a continuation-in-part of Ser. No. US
1985-811235, filed on 20 Dec 1985, now abandoned, said Ser. No. US
-397676 which is a division of Ser. No. US 1988-144574, filed on 15 Jan
1988, now abandoned which is a continuation-in-part of Ser. No. US
1987-115139, filed on 30 Oct 1987, now abandoned
DT Utility
FS Granted
INCL INCLM: 435/007.230
INCLM: 435/007.100; 435/007.210; 435/960.000; 530/351.000
NCLM: 435/007.230
NCLM: 435/007.100; 435/007.210; 435/960.000; 530/351.000
ICM: G01N033-74
ICS: G01N033-68; G01N033-60; C07K013-00
EXF 435/7.23; 435/7.21; 435/960; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 63 OF 76 USPTFULL
 AN 95:58232 USPTFULL
 TI Hybrid immunoglobulins
 IN Capon, Daffiel J., San Mateo, CA, United States
 PA Lasky, Lawrence A., Sausalito, CA, United States
 PI Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
 AI US 5428130 19950627
 RLI US 1992-986931 19921208 (7)
 Continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now
 patented, Pat. No. US 5225338 which is a continuation of Ser. No. US
 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964
 which is a continuation-in-part of Ser. No. US 1985-315015, filed on 23
 Feb 1989, now patented, Pat. No. US 5098353

DT Utility
 FS Granted
 LN.CNT 2630
 INCL INCLM: 530/350.000
 INCLM: 530/387.100; 536/023.400; 435/064.700
 NCLM: 530/350.000
 NCLM: 530/350.000
 NCLM: 435/069.700; 530/387.100; 536/023.400

IC [6]
 ICM: C07K013-00
 EXF 435/69.7; 435/252.3; 435/320.1; 530/350; 530/387.1; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 64 OF 76 USPTFULL
 AN 95:58116 USPTFULL
 TI Oncostatin M and novel compositions having anti-neoplastic activity
 IN Shoyab, Mohammed, Seattle, WA, United States
 PA Zaring, Joyce M., Seattle, WA, United States
 PI Margardt, Hans, Mercer Island, WA, United States
 PA Hansen, Marcia B., Seattle, WA, United States
 PA Brown, Thomas J., Poulsbo, WA, United States
 PA Oncogen Limited Partnership, Seattle, WA, United States (U.S.
 corporation)
 PI US 5428012 19950627
 AI US 1993-85279 19930701 (8)
 RLI Continuation of Ser. No. US 1989-428195, filed on 27 Oct 1989, now
 abandoned which is a division of Ser. No. US 1988-144574, filed on 15
 Jan 1988, now abandoned which is a continuation-in-part of Ser. No. US
 1987-115139, filed on 30 Oct 1987, now abandoned And a
 continuation-in-part of Ser. No. US 1987-46846, filed on 4 May 1987, now
 patented, Pat. No. US 5120535 which is a continuation-in-part of Ser.
 No. US 1986-935283, filed on 26 Nov 1986, now abandoned which is a
 continuation-in-part of Ser. No. US 1985-811235, filed on 20 Dec 1985,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 2150
 INCL INCLM: 514/012.000
 INCLM: 424/085.500; 424/085.100; 514/021.000; 530/350.000
 NCLM: 514/012.000
 NCLM: 424/085.100; 424/085.500; 514/021.000; 530/350.000

IC [6]
 ICM: C12P021-02
 EXF 530/350; 424/85.5; 424/85.1; 514/12; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 65 OF 76 USPTFULL
 AN 95:47502 USPTFULL
 TI Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
 IN Irie, Reiko F., Los Angeles, CA, United States

PA The Regents of the University of California, Oakland, CA, United States
 (U.S. corporation)
 PI US 5419904 19950530
 AI US 1993-26320 19930226 (8)
 RLI Continuation-in-part of Ser. No. US 1990-609803, filed on 5 Nov 1990,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 919
 INCL INCLM: 424/155.100
 INCLM: 424/142.100; 424/174.100; 435/240.260; 530/387.100; 530/387.700;
 INCLM: 530/387.900; 530/388.150; 530/388.800
 NCLM: 424/155.100
 NCLM: 530/387.900; 530/388.150; 530/388.800
 NCLM: 424/142.100; 424/174.100; 435/344.100; 530/387.100; 530/387.700;
 530/387.900; 530/388.150; 530/388.800

IC [6]
 ICM: A61K039-395
 EXF 435/387.7; 530/387.9; 530/388.22; 530/388.8; 530/388.15; 424/85.8;
 424/142.1; 424/174.1; 424/155.1; 435/240.26
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 66 OF 76 USPTFULL
 AN 95:1725 USPTFULL
 TI Nucleic acids encoding type I interferon variants
 IN Martal, Jacques, Jouy-en-Josas, France
 PI Degryse, Etich, Strasbourg, France
 PA Gaye, Pierre, Paris, France
 PI Charlier, Madia, Paris, France
 PA Charpigny, Gilles, Orleans, France
 PA Reinoud, Pierrette, Chailion, France
 PA Chaouat, Gerard, Paris, France
 PA Institut National de la Recherche Agronomique-I.N.R.A., Paris, France
 (non-U.S. corporation)
 PI US 5378823 19950103
 PI WO 9209691 19920611
 AI US 1992-915707 19920911 (7)
 WO 1991-FR953 19911129
 PRAI FR 1990-14945 19901129 PCT 371 date
 FR 1990-14946 19901129 PCT 102(e) date
 DT Utility
 FS Granted
 LN.CNT 909
 INCL INCLM: 536/023.520
 INCLM: 530/351.000; 435/069.510; 435/320.100; 935/010.000
 NCLM: 536/023.520
 NCLM: 435/069.510; 435/320.100; 530/351.000

IC [6]
 ICM: C07H021-04
 EXF 530/407; 530/351; 424/85.4; 424/85.7; 435/69.51; 435/69.7; 435/69.8;
 435/69.9; 435/172.1; 435/320.1; 435/252.3; 536/23.52; 935/10; 935/37;
 935/48; 935/69
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 67 OF 76 USPTFULL
 AN 93:108990 USPTFULL
 TI Gamma-interferon-leukotoxin gene fusions and uses thereof
 IN Potter, Andrew, Saskatoon, Canada
 PI Campos, Manuel, Saskatoon, Canada
 PA Hughes, Huw P. A., Saskatoon, Canada
 PA University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)
 PI Ciba-Geigy Canada, Ltd., Saskatoon, Canada (non-U.S. corporation)

PI US 5273889 19931228
AI US 1991-777715 19911016 (7)
RLI Continuation-in-part of Ser. No. US 1990-571301, filed on 22 Aug 1990
DT Utility
FS Granted
LN CNT 1127
INCL INCLM: 435/069.510
INCL: 435/069.500; 435/069.520; 435/069.700; 435/172.300; 435/243.000;
NCLM: 435/252.300; 435/320.100; 435/811.000; 536/023.100
NCL: 435/069.510
NCLM: 435/069.500; 435/069.520; 435/069.700; 435/243.000; 435/252.300;
NCL: 435/320.100; 435/811.000; 536/023.100
[5]
ICM: C12N015-23
ICS: C12N015-19; C07H015-12
EXF 435/69.5; 435/69.51; 435/69.52; 435/69.7; 435/252.3; 435/243; 435/172.3;
435/320.1; 435/81; 536/27; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 68 OF 76 USPTAFULL
AN 93:96042 USPTAFULL
TI Host transformed with yeast gene and ubiquitin/polypeptide fusions
IN Liu, Chung-Cheng, Foster City, CA, United States
Miller, Harvey I., Pleasant Hill, CA, United States
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5262322 19931116
AI US 1991-694522 19910430 (7)
RLI Division of Ser. No. US 1988-284281, filed on 14 Dec 1988, now patented, Pat. No. US 5108919 which is a continuation-in-part of Ser. No. US 1988-210909, filed on 24 Jun 1988, now patented, Pat. No. US 5156968
DT Utility
FS Granted
LN CNT 2176
INCL INCLM: 435/252.330
INCL: 435/069.700; 435/172.300; 435/195.000; 435/224.000; 435/252.300;
NCLM: 435/320.100; 536/023.200; 536/023.400
NCL: 435/252.330
NCLM: 435/069.700; 435/195.000; 435/224.000; 435/252.300; 435/320.100;
NCL: 536/023.200; 536/023.400
[5]
ICM: C12N001-21
EXF 435/252.33; 435/252.3; 435/69.7; 435/172.3; 435/195; 435/224; 435/320.1;
536/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 69 OF 76 USPTAFULL
AN 93:69752 USPTAFULL
TI Interleukin-2-leukotoxin gene fusions and uses thereof
IN Potter, Andrew, Saskatoon, Canada
Campos, Manuel, Saskatoon, Canada
Hughes, Huw P. A., Saskatoon, Canada
Veterinary Infectious Disease Organization, Saskatoon, Canada (non-U.S. corporation)
PA Ciba-Geigy Canada Ltd, Mississauga, Canada (non-U.S. corporation)
PI US 5238823 19930824
AI US 1990-571301 19900822 (7)
DT Utility
FS Granted
LN CNT 1164
INCL INCLM: 435/069.520
INCL: 435/069.100; 435/069.300; 435/069.500; 435/069.700; 435/172.300;
435/320.100; 435/240.100; 435/243.000; 435/252.300; 536/023.400;
935/022.000; 935/024.000; 935/027.000; 935/047.000; 935/066.000

NCL INCLM: 435/069.520
NCL: 435/069.100; 435/069.300; 435/069.500; 435/069.700; 435/243.000;
NCL: 435/320.100; 435/320.100; 435/325.000; 536/023.400
[5]
ICM: C12P021-02
EXF 435/69.1; 435/69.3; 435/69.5; 435/69.52; 435/69.7; 435/172.3; 435/320.1;
435/243; 435/240.1; 435/252.3; 536/27; 935/22; 935/24; 935/47;
935/66
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 70 OF 76 USPTAFULL
AN 93:54852 USPTAFULL
TI Lymphocyte homing receptor/immunoglobulin fusion proteins
IN Capon, Daniel J., San Mateo, CA, United States
Laskey, Laurence A., Sausalito, CA, United States
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5225538 19930706
AI US 1991-808122 19911216 (7)
RLI Division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833
DT Utility
FS Granted
LN CNT 2558
INCL INCLM: 530/387.300
INCL: 435/069.700; 530/388.730
NCLM: 530/387.300
NCL: 424/134.100; 435/069.700; 530/388.730
[5]
ICM: C07K013-00
ICS: C17N015-62
EXF 435/69.7; 530/387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 71 OF 76 USPTAFULL
AN 93:7024 USPTAFULL
TI Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use thereof
IN Stepkowski, Zenon, Malvern, PA, United States
Koprowski, Hilary, Wynnewood, PA, United States
Thurin, Magdalena, Philadelphia, PA, United States
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
PI US 5182192 19930126
AI US 1990-564115 19900806 (7)
RLI Division of Ser. No. US 1987-30537, filed on 27 Mar 1987, now patented, Pat. No. US 4971792, issued on 20 Nov 1990
DT Utility
FS Granted
LN CNT 721
INCL INCLM: 435/007.230
INCL: 435/007.900; 435/968.000; 435/007.250; 436/064.000; 436/813.000;
NCLM: 424/001.100; 424/009.000; 530/391.300
NCL: 424/001.490
NCLM: 424/001.530; 424/009.340; 435/007.230; 435/007.250; 435/007.900;
435/968.000; 436/064.000; 436/813.000; 530/391.300
[5]
ICM: G01N033-574
ICS: A61K049-00
EXF 435/7.23; 435/7.25; 435/7.92; 435/960; 435/7.9; 435/968; 436/512;
436/548; 436/64; 436/813; 530/387; 530/388; 530/828; 530/388.7;
530/388.8; 530/391.3; 424/1.1; 424/9

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 72 OF 76 USPTAFULL
INCL: 92:100931 USPTAFULL
TI Monoclonal antibodies against lymphoma-associated antigens, hybrid cell
lines producing these antibodies
IN Steplewski, Zenon, Malvern, PA, United States
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
PI US 5169775 19921208
AI US 1990-545590 59900629 (7)
RLI Continuation of Ser. No. US 1987-44285, filed on 3 Apr 1987
DT Utility
FS Granted
LN.CNT 1069
INCL: INCLM: 435/240.270
INCL: 530/388.100; 530/387.300; 530/388.800
NCL: 435/344.000
NCLM: 530/387.300; 530/388.100; 530/388.800
IC [5]
ICM: C12N005-12
ICS: C07K015-28; C12P021-08
EXF 530/387; 530/388.1; 530/388.8; 530/387.3; 435/240.27; 424/85.8; 935/104;
935/110; 935/107; 935/108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 73 OF 76 USPTAFULL
AN 92:42890 USPTAFULL
TI Hybrid immunoglobulins
IN Capon, Daniel J., San Mateo, CA, United States
PA Laskey, Laurence A., Sausalito, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5116964 19920526
AI US 1989-440625 19891122 (7)
RLI Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989
DT Utility
FS Granted
LN.CNT 2533
INCL: INCLM: 536/027.000
INCL: 435/069.700; 435/252.300; 435/320.110; 530/350.000
NCL: 536/023.500
NCLM: 424/134.100; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
NCL: 530/387.300; 536/023.510; 536/023.530
IC [5]
ICM: C07H021-04
ICS: C12N015-62; C12P021-02
EXF 435/69.7; 435/172.3; 435/252.3; 435/320; 436/512; 530/350; 530/387;
536/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 74 OF 76 USPTAFULL
AN 92:34077 USPTAFULL
TI DNA sequences encoding yeast ubiquitin hydrolase
IN Liu, Chung-Cheng, Foster City, CA, United States
PA Miller, Harvey I., Pleasant Hill, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5108919 19920428
AI US 1988-284281 19881214 (7)
RLI Continuation-in-part of Ser. No. US 1988-210909, filed on 24 Jun 1988
DT Utility
FS Granted
LN.CNT 2214

INCL INCLM: 435/224.000
INCL: 435/172.300; 435/240.200; 435/252.330; 435/252.300; 435/255.000;
435/320.100; 536/027.000
NCL NCLM: 435/224.000
NCL: 435/252.300; 435/252.330; 435/254.210; 435/320.100;
435/365.000; 536/023.200; 536/023.600
IC [5]
ICM: C12N009-60
ICS: C12N015-00; C07H015-12
EXF 435/91; 435/195; 435/224; 435/240.1; 435/252.3; 435/252.33; 435/255;
435/320; 536/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 75 OF 76 USPTAFULL
AN 90:89116 USPTAFULL
TI Monoclonal antibodies against glycolipid antigens
IN Steplewski, Zenon, Malvern, PA, United States
PA Koprowski, Hilary, Wynnewood, PA, United States
PA Thurnin, Magdalena, Philadelphia, PA, United States
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
PI US 4971792 19901120
AI US 1987-30537 19870327 (7)
DT Utility
FS Granted
LN.CNT 700
INCL: INCLM: 424/085.910
INCL: 530/380.000; 530/381.000; 530/387.000; 530/388.000; 530/389.000;
530/391.000; 530/395.000; 530/806.000; 530/808.000; 530/828.000;
424/093.000; 435/240.200; 435/240.260; 435/240.270
NCL NCLM: 424/001.490
NCL: 424/085.500; 424/085.700; 424/093.710; 424/137.100; 424/178.100;
424/183.100; 530/380.000; 530/381.000; 530/387.500; 530/388.700;
530/388.850; 530/391.300; 530/391.700; 530/395.000; 530/806.000;
530/808.000; 530/828.000
IC [5]
ICM: A61K039-395
ICS: C07K015-28
EXF 429/85; 429/86; 429/87; 429/85.8; 429/85.91; 429/93; 530/387; 530/809;
530/828; 530/808; 435/240.26; 435/240.27; 935/103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 76 OF 76 USPTAFULL
AN 89:58819 USPTAFULL
TI Monoclonal antibodies against melanoma-associated antigens and hybrid
cell lines producing these antibodies
IN Thurnin, Jan, Philadelphia, PA, United States
PA Koprowski, Hilary, Wynnewood, PA, United States
PA Herlyn, Weenhard, Wynnewood, PA, United States
PA Steplewski, Zenon, Malvern, PA, United States
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
PI US 4849509 19890718
AI US 1987-16902 19870220 (7)
DT Utility
FS Granted
LN.CNT 829
INCL: INCLM: 530/387.000
INCL: 530/389.000; 530/806.000; 530/828.000; 424/085.800; 435/068.000;
435/172.200; 435/172.300; 435/240.270
NCL NCLM: 530/388.200
NCL: 424/137.100; 424/156.100; 435/070.210; 435/329.000; 435/344.100;
530/388.850; 530/806.000; 530/828.000; 530/861.000
IC [4]
ICM: A61K039-395
ICS: C12N015-00; C07K015-04

EXE 530/387; 530/388; 530/389; 530/391; 530/806; 530/828; 424/85; 424/85.8;
435/68; 435/172.2; 435/240.27; 435/240.26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 114 1-8

L14 ANSWER 1 OF 8 USPTAFULL
AN 1998:134627 USPTAFULL
DN 98639396 CANCERLIT
TI Immunomodulatory fusion proteins for cancer
therapy (meeting abstract).
AU Zhao L; Chace D; Grosmaire L; Ledbetter J; Siegall C B; Fell H P
CS BMS Pharmaceutical Research Institute, Bristol-Myers Squibb, Seattle, WA
98121.
SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A2396.
ISSN: 0197-016X.
DT (MEETING ABSTRACTS)
FS ICD8
LA English
EM 199801

L14 ANSWER 2 OF 8 USPTAFULL
AN 1999:117645 USPTAFULL
TI Products and processes for regulation of gene recombination
IN Dreyfus, David H., Denver, CO, United States
Gelfand, Erwin W., Englewood, CO, United States
PA National Jewish Medical and Research Center, Denver, CO, United States
(U.S. corporation)
PI US 5959074 19990928
AI US 1997-807332 19970228 (8)
PRAI US 1996-12616P 19960301 (60)
DT US 1996-23064P 19960802 (60)
Utility
FS Granted
LN.CNT 2196
INCL INCLM: 530/300.000
NCL INCLM: 530/324.000
NCLM: 530/300.000
NCLM: 530/324.000
ICS: 530/324.000
[6]
ICM: C07K014-00
EXF 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/330;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 8 USPTAFULL
AN 1999:72572 USPTAFULL
TI DNA transcription unit vaccines that protect against avian influenza
viruses and methods of use thereof
IN Webster, Robert, Memphis, TN, United States
PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S.
corporation)
PI US 5916879 19990629
AI US 1996-747286 19961112 (8)
DT Utility
FS Granted
LN.CNT 1891
INCL INCLM: 514/044.000
INCLM: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;
424/816.000
NCL INCLM: 514/044.000
NCLM: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;
536/023.720
[6]
ICM: A61K048-00
ICS: C12N015-87; C12N015-44
EXF 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 8 USPTAFULL
AN 1998:134627 USPTAFULL
TI Yeast-based delivery vehicles
IN Duke, Richard C., Denver, CO, United States
Frank, Rexham S., Wellington, CO, United States
PA University Technology Corporation, Boulder, CO, United States (U.S.
corporation)
PI US 5830463 19981103
AI US 1994-340185 19941115 (8)
RUI Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now
patented, Pat. No. US 5413934
DT Utility
FS Granted
LN.CNT 1929
INCL INCLM: 424/093.510
INCLM: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300;
435/069.100
NCL INCLM: 424/093.510
NCLM: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000
ICS: C12N015-09; A61K048-00
[6]
ICM: C12N015-00
EXF 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31;
514/44; 935/62; 935/52; 935/55; 935/56; 935/57; 935/34; 935/32;
424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 8 USPTAFULL
AN 1998:108036 USPTAFULL
TI Recombinant canine herpesviruses
IN Haanes, Elizabeth J., Berthoud, CO, United States
Frank, Rexham S., Wellington, CO, United States
PA Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
PI US 5804197 19980308
AI US 1996-680726 19960712 (8)
RUI Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996
DT Utility
FS Granted
LN.CNT 5536
INCL INCLM: 424/229.100
INCLM: 424/199.100; 435/235.100; 435/320.100
NCL INCLM: 424/229.100
NCLM: 424/199.100; 435/235.100; 435/320.100
ICS: 424/199.100; 435/235.100; 435/320.100
[6]
ICM: A61K039-245
EXF ICS: A61K039-00; C12N007-01; C12N015-00
424/229.1; 424/199.1; 435/235.1; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 8 USPTAFULL
AN 1998:57716 USPTAFULL
TI Aptamers specific for biomolecules and methods of making
IN Griffin, Linda, Atherton, CA, United States
Albrecht, Glenn, Redwood City, CA, United States
Latham, John, Palo Alto, CA, United States
Leung, Lawrence, Hillsborough, CA, United States
Vernaas, Eric, Oakland, CA, United States
Toole, John J., Burlingame, CA, United States
PA Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)
PI US 5756291 19980526
AI US 1995-484192 19950607 (8)
RUI Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now

DT abandoned
 FS Utility
 LN.CNT 8242
 INCL INCLM: 435/006.000
 INCLM: 536/023.100; 530/413.000; 935/077.000; 935/078.000
 NCLM: 435/006.000
 NCLM: 530/413.000; 536/023.100
 IC [6]
 ICS: C120001-68
 ICS: C07K001-14; C07H021-04; C07H021-02
 ICS: 435/6; 935/77; 935/78; 530/413; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 EXF 435/6; 935/77; 935/78; 530/413; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L14 ANSWER 7 OF 8 USPATEFULL
 AN 1998:54490 USPATEFULL
 TI Recombinant canine herpesviruses
 IN Haanes, Elizabeth J., Boulder, CO, United States
 Frank, Rexann S., Wellington, CO, United States
 PA Heeka Corporation, Ft. Collins, CO, United States (U.S. corporation)
 PI US 5793235
 AI US 1996-602010
 DT Utility
 FS 19960215 (8)
 LN.CNT 3143
 INCL INCLM: 424/229.100
 INCLM: 424/147.100; 435/235.100; 530/388.300; 530/395.000
 NCLM: 424/229.100
 NCLM: 424/147.100; 435/235.100; 530/388.300; 530/395.000
 IC [6]
 ICS: A61K039-245
 ICS: C12N007-01; C07K001-00; C12P021-02
 ICS: 424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 EXF 424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L14 ANSWER 8 OF 8 USPATEFULL
 AN 1998:36732 USPATEFULL
 TI Polynucleotide tuberculosis vaccine
 IN Content, Jean, Rhode-Saint-Genese, Belgium
 Huygen, Kris, Brussels, Belgium
 Liu, Margaret A., Rosemont, PA, United States
 Montgomery, Donna, Chalfont, PA, United States
 Ulmer, Jeffrey, Chalfont, PA, United States
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PA N. V. Innogenetics S.A., Ghent, Belgium (non-U.S. corporation)
 PI US 5736524
 AI US 1994-338992
 DT Utility
 FS 19941114 (8)
 LN.CNT 1346
 INCL INCLM: 514/044.000
 INCLM: 435/006.000; 435/069.100; 435/172.300; 435/375.000; 435/320.100;
 935/062.000; 935/056.000; 935/034.000; 935/065.000
 NCLM: 514/044.000
 NCLM: 435/006.000; 435/069.100; 435/320.100; 435/375.000
 IC [6]
 ICS: A61K048-00
 ICS: C07H021-00; C12N015-79; C12N015-63
 ICS: 435/320.1; 435/6; 435/69.1; 435/172.3; 435/243; 435/252.1; 514/44;
 935/62; 935/65; 935/66; 935/70; 935/71; 935/73; 935/34; 935/72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 EXF 435/62; 935/65; 935/66; 935/70; 935/71; 935/73; 935/34; 935/72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 19 and treat?
L18 2 L9 AND TREAT?

=> d 118 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 2001:713568 CAPLUS:
DN 135:268188
TR Methods of making chimeric protein hPRLA/IL-2 and uses as a
bi-functional cancer treatment agent
IN Chen, Wen Y.; Wagner, Thomas E.
PA Greenville Hospital System, USA
SO PCT Int. Appl., 47 pp.
DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001070985	A2	20010927	WO 2001-US9284	20010323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-191457P P 20000323

L18 ANSWER 2 OF 2 USPTFULL
AN 2001:194148 USPTFULL
TI PROLACTIN ANTAGONISTS AND USES THEREOF
IN WALKER, AIMEE M., RIVERSIDE, CA, United States
PI US 2001036662 A1 20011101
A1 US 1998-65330 A1 19980423 (9)
WO 1997-US1435 19970130

DT Utility
ES APPLICATION
LN.CNT 1083
INCL INCLM: 435/320.100
NCL INCLS: 536/023.500
NCL NCLM: 435/320.100
NCL NCLS: 536/023.500
IC [7]

ICM: C12N015-63
ICS: C07H021-04; C12N015-00; C12N015-74; C12N015-70; C12N015-09
CAS INDEXING IS AVAILABLE FOR THIS PATENT.